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Vaccination with BCG has variable efficacy in protection against pulmonary 
tuberculosis (TB), thus highlighting the critical need for development of more 
effective TB vaccines. Increasing evidence indicates a role for CD8 T cells in 
controlling chronic infections, hence novel TB vaccines may benefit from induction of 
CD8 T cell responses. The aim of this project was to compare the breadth and 
magnitude of CFP10 and ESAT6-specific CD8 T cell responses in individuals with 
latent Mycobacterium tuberculosis (MTB) infection (LTBI) and active TB disease, and 
further define MTB-specific CD8 T cell phenotypes associated with latent infection 
and active disease. Ex vivo IFNγ Elispots and proliferation assays were used to 
identify immunodominant ESAT6 and CFP10 15mer peptides targeted by CD8 T 
cells in LTBI and TB donors. A multiparameter flow cytometry pa el was designed 
and optimized to assess turnover, susceptibility to apoptosis and terminal 
differentiation/senescence in CD8 T cells from TB and LTBI donors. Bcl-2, Ki67, 
CD95, CD57, CD127 and IFNγ were thus measured in each group. A subset of TB 
donors were analyzed longitudinally at <1week, 2 months, and 6 months after 
initiation of anti-TB treatment. CD8 T cells in patients with TB exhibited poor 
proliferative capacity, compared with LTBI. CD8 T cells in LTBI donors recognized a 
significantly greater breadth of CFP10 peptides than TB donors, however there was 
no difference between LTBI and TB in the breadth of recognition to ESAT6 peptides. 
Bcl-2 and CD57 expression were increased in the total CD8 T cell population in 
individuals with TB disease. CD127 expression was increased on MTB-specific CD8 
T cells, relative to the total CD8 T cell population, in LTBI but not TB donors. Results 
from longitudinal data suggest that initiation of anti-TB treatment may reverse the 
phenotype seen in TB disease. Together these data suggest that differential 
recognition of CFP10 regions by CD8 T cells may distinguish between LTBI and TB 
disease. Additionally, the greater proliferative capacity of MTB-specific CD8 T cells in 
LTBI donors suggests differential functional capacities of MTB-specific CD8 T cells in 
latent and active TB disease. Overall, MTB-specific CD8 T cells in TB have a 
phenotype indicative of reduced functional capacity and higher susceptibility to 
apoptosis, relative to MTB-specific cells in LTBI, suggesting MTB-specific CD8 T 
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Mycobacterium tuberculosis (MTB) is responsible for approximately 1.7 million 
deaths worldwide (WHO 2010). 90% of MTB-infected individuals remain 
asymptomatic, providing strong evidence that the host immune response is usually 
successful in containing the infection. Although specific components of host cellular 
immunity that are responsible for successful containment of bacterial replication are 
not fully understood, increasing evidence from both human and non-human primate 
models indicate a significant role for CD8 T cells in successful immune control of 
MTB. However, a paucity of data remains regarding the epitope specificity, functional 
capacity and phenotype of MTB-specific CD8 T cells that are associated with 
successful immune control of MTB infection. In other chronic infection models, 
antigen-specific CD8 T cells have been shown to undergo a process of functional 
exhaustion, characterized by decreased cytokine production, cytotoxic activity, and 
proliferative capacity. It is not known whether MTB-specific CD8 T cells are similarly 
functionally exhausted in individuals with chronic MTB infection, thereby contributing 
to loss of immune control and progression to symptomatic, active disease. The 
underlying hypothesis of this study is that successful immune control of MTB 
infection is associated with maintenance of highly functional MTB-specific CD8 T 
cells. The specific aims were to identify MTB epitopes targeted by CD8 T cells, and 
to characterize the phenotype of MTB-specific CD8 T cell responses in individuals 













1.1 The innate immune system 
 
The first line of defense against invading pathogens is the innate immune system. It 
detects highly-conserved pathogen associated molecular patterns (PAMPs), and 
mounts a rapid, short-lived response (Iwasaki and Medzhitov 2010). Upon pathogen 
clearance, cells of the innate immune system retain no memory of the pathogen 
hence their response to a second invasion will be similar in magnitude and duration. 
The first barrier by the innate immune system consists of antimicrobial compounds 
found in fluids such as tears, mucus and sweat. The skin also provides a physical 
barrier against pathogens. If these mechanisms are traversed, the pathogen will 
encounter inflammatory proteins in the serum that may neutralize a pathogen before 
it invades any cells. For example, such proteins may bind to the surface of the 
pathogen, making it more susceptible to phagocytosis, in a process known as 
opsonization. Monocytes, macrophages, dendritic cells (DCs), neutrophils and 
natural killer (NK) cells are cells of the innate immune system. 
Monocytes are phagocytic leukocytes that are present in the blood. They are 
precursors of differentiated tissue-specific macrophages, which along with DCs also 
possess phagocytic properties. DCs and macrophages reside in interstitial spaces, 
for example near the surface of the skin. Upon encounter with a pathogen, these 
cells will recognize PAMPs via toll like receptors (TLRs), which can be found on their 
cell surface (to recognize extracellular pathogens) or intracellularly (to recognize 
viruses). Signaling through TLRs leads to cell activation and maturation. Chemo-
attractants secreted by activated macrophages will recruit polymorphonuclear 
granulocytes known as neutrophils to the site of infection. Upon ingestion of the 
pathogen, both macrophages and neutrophils undergo a respiratory burst, which 
fuels the release of bactericidal molecules such as reactive oxygen species. In 
addition to killing the pathogen, the release of these molecules plays a role in cell 
signaling (Forman and Torres 2002). The development of homing receptors occurs 
during DC maturation and allows DCs to travel to areas where there is a high 
concentration of cells of the adaptive immune system, such as T cells. Mature DCs 
will increase IL-12 and IL-15 production causing proliferation of naïve T cells and 
increased activation of DCs, respectively (Schluns and Lefrancois 2003). Mature 












which are required for antigen presentation to naïve T cells. Activated DCs form a 
chemokine gradient that attracts other cells to the site of infection, including T cells. 
In this way, DCs serve as an important link between the innate and the adaptive 
immune system (Vivier, Raulet et al. 2011). 
While DCs link the innate and adaptive immune system, NK cells are said to 
possess properties of both. NK cells are rapidly responding effector cells with 
cytolytic capacity. NK cells are biased to produce IFNγ in response to antigen 
encounter, however they also produce TNFα. Both of these cytokines assist in DC 
maturation.  In the case of chronic antigen stimulation, NK cells have been known to 
produce IL-10 (Vivier, Raulet et al. 2011). NK cells will respond to cells displaying 
markers of infection by facilitating apoptosis of the target cell. NK cells are 
traditionally classified as cells of the innate immune system, however recent 
evidence has shown that they are capable of responding m re rapidly to previously 
encountered antigen (Sun, Beilke et al. 2009), a characteristic typical of the adaptive 
immune system. 
 
1.2 The adaptive immune system 
 
The adaptive immune system evolved to counter pathogens that managed to evade 
the innate immune system. It is distinguished by its later response time, its ability to 
recognize a wide range of un-conserved pathogen-derived molecules, and its 
capacity to mount a more rapid response upon a second exposure to the same 
pathogen; i.e. immune memory. There are two arms of the adaptive immune system, 
including humoral and cell-mediated immunity. 
 
1.2.1 Humoral response 
 
The humoral immune response is mediated by antibodies (also known as 
immunoglobulins; Ig), which are secreted by bone marrow derived cells (B cells). 
Prior to antigen exposure, B cells will develop relatively moderate antigen-specificity 
via rearrangement of genes encoding for antibody segments. They then exit the 
bone marrow as immature B cells. These immature B cells will develop into naïve B 












the body. There are five known classes or isotypes of antibodies: IgG, IgM, IgE, IgA 
and IgD, which are composed of a heavy chain and a light chain. There are four 
genes encoding for the heavy chain (VH, D, JH, and CH), which may produce nine 
different types of heavy chain protein. There are three genes encoding for the light 
chain region (VL, JL, and CL) which may produce two types of light chain protein 
(Bonilla and Oettgen 2010). 
The second phase of B cell development occurs during their circulation through 
secondary lymphoid organs such as the spleen, mucosal associated lymphoid 
tissue, and lymph nodes. This second phase is antigen-dependent. Most antigens 
require T cell help to elicit a B cell response. A sequence of two signals occurs, firstly 
to allow B cells to develop the capacity to interact with T cells, and secondly to allow 
B cells to present antigen on their cell surface to CD4 T helper cells. Once these two 
signals are complete, B cells will clonally expand to produce antibodies with a 
moderate affinity to the antigen. The dose of antigen and its binding affinity 
determine the magnitude of B cell expansion (Elgueta, de Vries et al. 2010), and 
whether cells will differentiate into memory B cells, long lived plasma cells (PCs) or 
short lived PCs. Sufficient antigen exposure will cause some activated B cells to 
travel to the follicle and establish a germinal centre. In the germinal centre, B cells 
producing IgM and IgD antibodies may undergo an isotype change through VDJ 
gene rearrangement, to produce other types of antibodies such as IgA, IgE and IgG. 
This process is known as class switching. In the variable regions of heavy and light 
chain genes (VH and VL), somatic hyper-mutation occurs concurrently with class 
switching. This leads to the generation of antibodies with a higher affinity for the 
antigen and is known as affinity maturation. Secreted antibodies are involved in the 
complement system, which is a cascade of reactions designed to lead to the 
clearance of an extracellular pathogen. The antibodies bind to their target and 
mediate its phagocytosis by innate cells. Antibodies can also cause chemotaxis of 
other cells of the immune system, and inflammation. 
After approximately two weeks of initial exposure to an antigen, B cells will 
synthesize high affinity antibodies. If re-infection occurs, high affinity antibodies can 
be synthesized within one week of exposure, due to the memory capacity of these 












lived effector cells. Memory B cells are postulated to differentiate into (and hence 
replenish) the long lived PC population (Bonilla and Oettgen 2010). 
 
1.2.2 Cell-mediated immunity 
 
CD4 and CD8 T cells are responsible for cell-directed, highly specific immune 
responses by the adaptive immune system. The high antigen-specificity achieved by 
somatic recombination of T cell receptor (TCR) genes to generate TCR diversity 
involves a process analogous to Ig gene rearrangement. Immature T cells originate 
in the thymus where they undergo a selection process, which eliminates self-reactive 
cells. They circulate through the body where they may encounter foreign antigens in 
the peripheral lymphoid organs. Exposure to an MHC-peptide complex that is bound 
by their TCR promotes maturation into a particular effector subset, as dictated by the 
cytokine environment. Two signals are necessary for the activation of naïve T cells: 
the first signal is the interaction between the TCR on a T cell and the MHC-antigen 
complex on an APC. The second signal involves co-stimulatory molecules, 
specifically B7.1 or B7.2 on the APC, and CD28 on the T cell. Without this second 
signal, T cells binding to the MHC-antigen complex will become anergic. Once a T 
cell is activated, cytokine production by APCs provides a third signal that directs T 
cell differentiation into various effector subsets (Williams and Bevan 2007). 
There are two main types of conventional T cells: CD8 T cells and CD4 T cells. A 
definitive difference between them is their recognition of antigens bound to either 
MHC I or MHC II, respectively. MHC I binds peptides from cytosolic antigens. These 
peptides have been synthesized in the cytoplasm via proteosome-mediated 
degradation of cytosolic proteins. MHC I peptides are usually eight to ten amino 
acids long, however recent research shows that CD8 T cells can recognize peptides 
displayed by MHC I that are up to 25 amino acids long (Bell, Burrows et al. 2009). 
MHC II binds peptides from extracellular antigens; the peptide length is more flexible 
than MHC I because of structural differences in the peptide binding groove. 
Extracellular pathogens or antigens are internalized within phagosomes that fuse 
with lytic vesicles to form phagolysosomes. This process results in the digestion of 












on the cell surface of professional APCs. In contrast, MHC I is expressed on all 
somatic cells. Both CD4 and CD8 T cells can recognize super-antigens such as 
Staphylococcal enterotoxin B; these super-antigens may bind to MHC II molecules 
that are already bound to peptide, or even bind directly to the T cell receptor, causing 
T cell activation (Adachi and Davis 2011).  
A similarity between CD4 and CD8 T cells is their differentiation and memory 
properties. In the event of a second exposure to a pathogen that causes an acute 
infection, memory T cells will differentiate into a rapidly expanding effector cell 
population and home to the site of infection (Sallusto, Geginat et al. 2004; Janossy, 
Barry et al. 2008). The resolution of an acute infection results in clearance of the 
pathogen and correlates with contraction of the effector cell population. The surviving 
T cells develop a central memory or effector memory phenotype, which differ in their 
response to re-encounter with antigen. Figure 1.1 shows effector T cell differentiation 
during an acute infection and generation of memory T cell responses. Central 
memory cells are thought to re-circulate in secondary lymphoid organs more readily 
than effector memory cells. They proliferate rapidly and differentiate into effector 
memory cells upon re-encounter with antigen. Effector memory cells have reduced 
proliferative capacity and can produce signaling molecules such as cytokines that 
activate other cells to neutralize the pathogen (Janeway 2005; Williams and Bevan 
2007). The effector functions differ between CD4 and CD8 T cells, and even within 
subsets of each cell type. To summarize, the difference between memory and naïve 
T cells is that memory cells have a more rapid and robust response to antigen 
stimulation (Sallusto, Geginat et al. 2004). Central memory and effector memory T 
cell populations can be found in the blood after an infection has been cleared. They 
are maintained by homeostatic cytokines such as IL-7 and IL-15 that allow cells 














Figure 1.1. T cell differentiation in an acute model of infection. IL-15 promotes activation of DCs 
presenting antigen to T cells on MHC molecules. Activated T cells will clonally expand, at least partly 
due to signaling mediated by IL-2. IL-15 may cause further expansion and activation. With time, the 
infection is resolved and the T cell population contracts to become a small pool of long-lived memory 
cells that are maintained by IL-7. IL-15 is also responsible for memory cell turnover. Taken from 
(Schluns and Lefrancois 2003). 
 
CD4 T cells are also known as helper T cells. There are various CD4 T cell effector 
subsets, which play different roles in modulating the immune system. Th1 CD4 cells 
recognize antigens displayed on MHC II molecules on the surface of APCs and 
respond by producing IFNү. This cytokine activates macrophages and enhances 
phagocytosis and intracellular killing of pathogens (Flynn and Chan 2001; North and 
Jung 2004; Grotzke and Lewinsohn 2005). Th1 cells also assist in priming and 
maintenance of CD8 T cell responses as shown in viral models of infection (Flynn 
and Chan 2001; Ahlers and Belyakov 2010; Sharma, Hou et al. 2010). Other well 
characterized CD4 T cell subtypes are responsible for B cell activation (Th2 cells), 
eliminating fungi and extracellular bacteria (Th17 cells), and suppressing effector 
cells (regulatory T cells) (Zielinski, Corti et al. 2011). Some CD4 T cells are known to 
secrete granulysin and perforin, which are responsible for apoptosis of infected 
target cells (Flynn and Chan 2001). Upon exposure to antigen, naïve CD8 T cells 
differentiate into effector cells with the ability to kill target cells. They do so via the 
release of cytotoxic molecules such as granzymes and perforin (Seder and Ahmed 












and Ahmed 2003), which are responsible for cell-targeted damage (Ratner and Clark 
1993). 
The phenotype of CD8 T cells differs between acute (where antigen is cleared) 
and chronic (where antigen persists) infections. Human immunodeficiency virus 
(HIV), lymphocytic choriomeningitis virus (LCMV) and hepatitis C virus (HCV) are 
examples of chronic viral infections in which persistent antigen stimulation causes 
antigen-specific CD8 T cells to become less functional with time in a process known 
as T cell exhaustion (Yi, Cox et al. ; Williams and Bevan 2007). Additionally, the 
long-lived memory T cell population is thought to deteriorate in the event of continual 
antigen exposure, and this is reflected by reduced IL-7 receptor expression on the 
cell surface (Singh, Gowthaman et al. 2010). In mouse models of chronic viral 
infections, there is a stepwise loss of T cell function as they become exhausted. T 
cells producing multiple cytokines such as IFNγ, IL-2 and TNFα will eventually lose 
their cytokine production capacity, remaining with only the capacity to produce IFNγ 
(Fuller, Khanolkar et al. 2004). The exhausted T cells will constitutively express 
inhibitory receptors, such as PD-1, Tim-3 and Lag-3, and expression of these 
regulatory molecules have been associated with diminished proliferative capacity 
and T cell dysfunction (Yi, Cox et al. 2010). As the chronic infection persists, the 
population of antigen-specific T cells will deteriorate due to the deletion of exhausted 
T cells (Yi, Cox et al. 2010). CD8 T cells in a mouse model of chronic infection 
display reduced target cell killing compared to an acute model of the same infection. 
However, the reduced cytotoxicity in chronic infection may be antigen-dependent 
(Fuller, Khanolkar et al. 2004). 
Studies of other chronic infections have identified markers of exhaustion, 
apoptosis and replicative senescence, including PD-1, CTLA-4, CD95 and CD57 
(Moss and Khan 2004; Sabbaj, Heath et al. 2007; Wherry, Ha et al. 2007; Blackburn, 
Shin et al. 2009; Wood, Twigg et al. 2009). PD-1 is upregulated in exhausted CD8 T 
cells, and blockade of PD-1 signaling has been found to restore proliferative capacity 
in a mouse model of LCMV (Barber, Wherry et al. 2006; Day, Kaufmann et al. 2006). 
CD57 is up-regulated on antigen-specific cells, and its expression is associated with 
immunosuppression (Wood, Twigg et al. 2009). CTLA-4 mRNA is over-expressed in 
exhausted CD8 T cells in a LCMV mouse model (Wherry, Ha et al. 2007). However, 












2006). In HIV infection, antigen-specific CD8 T cells have increased susceptibility to 
activation induced cell death via CD95/Fas pathway (Petrovas, Casazza et al. 2006). 
Figure 1.2 illustrates the gradual deletion of antigen-specific T cells in a chronic viral 
infection model. 
 
Figure 1.2. The effect of antigen load on the cytokine profile of T cells. Antigen-specific cytokine 
producing CD8 T cell populations decline in number with increasing antigen load in a chronic infection 
model. The capacity to produce multiple cytokines simultaneously (polyfunctionality) is also lost, 




1.3 Tuberculosis Epidemiology 
 
Tuberculosis (TB) is a major global health problem, with over 9 million new cases of 
TB per year, and over 1.6 million deaths per year (WHO 2010). Upon infection with 
Mycobacterium tuberculosis (MTB), 10% of individuals will develop TB disease 
(Ottenhoff 2009);  approximately 5% will develop TB within 2 years and 5% will 
develop TB later in life (WHO 2009). The majority of MTB-infected individuals will 












the bacteria within granulomas (Algood, Chan et al. 2003). Within groups at high risk 
of infection, only 22% to 33% of new cases are due to recent transmission of MTB, 
implying that reactivation of asymptomatic latent infections are responsible for a 
large proportion of new TB cases (van Pinxteren, Cassidy et al. 2000).  HIV 
coinfection further increases the rate of reactivation (WHO 2009). 
 
TB is particularly endemic to African regions, as shown in Figure 1.3. In South 
Africa, the incidence of TB in 2009 was 948 per 100 000 per year, which is one of 
the highest incidence rates in the world and includes a rapidly increasing frequency 
of infections with multi-drug resistant (MDR) and extensively drug resistant (XDR) 
MTB strains (Johnson, Warren et al. 2010). In 2009, there were 230 deaths due to 
TB per 100 000 per year, making TB the most common notified natural cause of 










Figure 1.3. Estimated TB incidence rates by country 2009. South Africa has one of the highest TB 
incident rates in the world. Taken from (WHO 2010). 
The failure to complete short course treatment exacerbates the TB problem, leading 
to the development of MDR and XDR strains. Resistance to both isoniazid and 
rifampicin as found in MDR TB means that first line treatment is ineffective on these 
isolates, and could lead to the development of other drug resistant strains such as 
XDR TB which, in addition to isoniazid and rifampicin resistance, is also resistant to 
a fluoroquinolone and a second-line injectable drug (Becerra, Appleton et al. 2011). 
Approximately 20% of all new incident TB cases globally are estimated to have MDR 












treatment are urgently needed to combat the spread of MDR and XDR TB.  
The global burden of TB disease is being addressed by the WHO millennium 
development goals, which aim to reverse the incidence of TB by 2015 (WHO 2010). 
In spite of this, TB case notification rates have risen nearly four times in the last 
twenty years (Karim 2009). One cause for this is HIV co-infection, which is known to 
play a role in the development of TB disease (Figure 1.4). HIV/TB co-infection is 
particularly endemic to non-industrialized countries (Corbett, Watt et al. 2003). The 
WHO African region accounted for 80% of the HIV-associated TB incident cases 
globally (WHO 2010). 
A key area of focus in combating the TB epidemic is vaccine development. The 
only currently licensed TB vaccine, Bacillus Calmette-Guérin (BCG), provides 
inadequate protection against pulmonary TB. HIV-infected infants have an increased 
risk of disseminated BCG disease (Hesseling, Johnson et al. 2009). Novel TB 
vaccines are currently being developed and tested in phase I and II clinical trials. 
AERAS-402 is currently in phase II trials in Kenya (Abel, Tameris et al. 2010); 
MVA85A (Scriba, Tameris et al. 2010) and M72 are currently in phase II trials in 
South Africa. 
 
1.4 Diagnosis of MTB infection 
 
Exposure to MTB may lead to clearance or to persistent infection. Established MTB 
infection may result in development of clinical disease or asymptomatic latent 
infection (LTBI). LTBI has been described as “immunological sensitization to 
antigens synthesized by MTB in the absence of clinical symptoms” (Barry, Boshoff et 
al. 2009). Tuberculin skin tests (TST) have been used to identify MTB-infected 
individuals. Upon injection of mycobacterial proteins under the skin, memory T cell 
responses to the bacteria are detected in the form of redness and swelling at the site 
of injection. TST positivity is not always a reliable measure of MTB infection, as non-
tuberculous mycobacteria, a history of cured TB disease, or even BCG vaccination 
could result in a false positive; immunosuppression could result in a false negative. 












(IGRAs) have recently been developed, including the T-SPOT.TB Elispot assay 
(Oxford Immunotec, Oxford, UK), and QuantiFERON®-TB Gold In-Tube (QFN; 
Cellestis Limited, Carnegie, Victoria, Australia) ELISA assay (Lalvani and Pareek). 
Both IGRA assays detect IFNγ production by T cells in response to highly 
immunogenic MTB proteins, namely early secretory antigenic target 6 (ESAT6) and 
culture filtrate protein (CFP10) (Lalvani, Brookes et al. 1998; Pathan, Wilkinson et al. 
2000; van Pinxteren, Cassidy et al. 2000; Lewinsohn, Zhu et al. 2001; Caccamo, 
Meraviglia et al. 2006; Lalvani and Pareek 2010), as well as TB7.7 in the QFN 
assay. 
Both ESAT6 and CFP10 are expressed by MTB, but not BCG, which allows for 
the distinction between immune responses induced by MTB infection versus BCG 
vaccination. They belong to the ESAT6 family of proteins, all of which are 
approximately 100 amino acids long (Brodin, Rosenkrands et al. 2004). Strong 
cellular immune responses to ESAT6 and CFP10 have been found in both animal 
and human models of infection, with a vast majority of TB diseased individuals 
recognizing one or both of these proteins (Grotzke and Lewinsohn 2005). ESAT6 is 
known to induce host membrane lysis as well as specific cytokine responses, such 
as IFNγ production (Grotzke and Lewinsohn 2005; de Jonge, Pehau-Arnaudet et al. 
2007; Stanley, Johndrow et al. 2007). For this reason, both ESAT6 and CFP10 are 
relevant when measuring MTB-specific responses in humans using IGRAs. 
  Pulmonary TB diseas  is more readily detected due to the presence of clinical 
symptoms such as coughing for over two weeks, night sweats, weight loss, reduced 
appetite, fatigue and weakness. Nonetheless, clinical symptoms alone are 
insufficient for a TB diagnosis. The current gold standard for diagnosis is the culture 
of sputum from a patient in order to grow out MTB that may be present. Another 
popular method of TB disease detection is PCR amplification of bacterial DNA (Yang 
and Rothman 2004).  
After diagnosis of TB disease, patients are prescribed anti-TB medication, which 
decreases their antigen load thus altering the dynamics of the host immune 
response (Barry, Boshoff et al. 2009; Russell, Barry et al. 2010). Standard short 
course chemotherapy guidelines for TB treatment in South Africa prescribe the 












months, followed by rifampicin and isoniazid administration daily for 4 months 
(Department of Health 2009). 
Distinguishing between latent infection and active TB disease on an 
immunological basis is difficult, as current scientific opinion points to a spectrum of 
latent infection (Dheda, Schwander et al. 2010). This spectrum ranges anywhere 
from low levels of inactive bacteria effectively contained by immune cells, to the 
presence of replicating bacteria in the absence of clinical symptoms. Factors such as 
number and size of granulomas, rate of bacterial replication, and clinical symptoms 
vary between infection and disease states (Barry, Boshoff et al. 2009). Figure 1.4 
portrays MTB infection as a spectrum of infection and disease. Little is known about 
factors contributing to the transition from latency to active disease (Flynn, Hanson et 
al. 2010), hence it is necessary to analyze in detail the host immune response to 
MTB infection that is either controlled (latent) or uncontrolled (active disease).  
 
 
Figure 1.4. Tuberculosis is a spectrum from infection to disease. Increasing bacterial load is 
purported to cause the change from quiescent infection to clinical disease. HIV is also thought to 















1.5 Pathogenesis and the adaptive immune response to MTB 
 
MTB is found in aerosol droplets that are transmitted when a person with TB disease 
coughs. Once the bacilli have entered the body they are recognized by alveolar 
macrophages via TLRs and phagocytosed. Phagolysosome formation will result in 
the destruction of most phagocytosed pathogens. However, MTB has been shown to 
prevent phagolysosome formation as a mechanism of immune evasion (Winau, 
Hegasy et al. 2005). The macrophage mounts a pro-inflammatory response, which 
includes recruitment of mononuclear cells and increased vascularization at the site of 
infection. A tightly packed group of cells is formed in order to contain bacterial 
replication. Cells of the adaptive immune system become part of this cell cluster; it 
develops a structure and is known as a granuloma. CD4 T cells within granulomas 
may recognize MTB antigens displayed on the macrophage cell surface and mount a 
Th1 response involving IFNү production and the priming and maintenance of CD8 T 
cells. Additionally, some CD4 T cells will secrete granulysin and perforin (Flynn and 
Chan 2001). However, due to inflammation and increased cell necrosis, the structure 
of the granuloma can become compromised, and rupture to free the bacteria within it 
(Russell, Barry et al. 2010). 
 
Research on the role of the adaptive immune system in containing MTB has 
largely focused on cellular immunity, and several previous studies in humans have 
compared the immune response of latently infected individuals to the response in 
individuals with TB disease (Flynn 2004). With regard to antigen-specificity, ‘latency-
associated antigens’ such as Rv2660 and Rv2659 have been identified, and are 
preferentially recognized by CD4 T cells of MTB infected individuals with no clinical 
symptoms of disease (Govender, Abel et al. 2010). Cytokine production has been 
extensively compared, and differential polyfunctional cytokine production capacity 
has been shown by three recent studies. One paper demonstrated an increased 
frequency of IL-2, IFNγ, and TNFα triple-producing CD4 T cells in TB disease 
compared to LTBI, when stimulated by various MTB antigens (Ag85B, 16KDa, 
ESAT6) in both long-term and short-term assays (Caccamo, Guggino et al. 2010). 
This paper also found significantly more IL-2+IFNγ+ CD4 T cells in LTBI compared 
to TB disease, and suggested that this was a result of lower antigen load in the 












specific single-positive TNFα-producing CD4 T cells were the dominant population in 
peripheral blood of TB diseased patients, and that their increased frequency could 
be used to discriminate between active disease and latent infection (Harari, Rozot et 
al. 2011). This finding is echoed by Day et al, who show that patients with smear 
positive TB have reduced frequencies of polyfunctional CD4 T cells and increased 
TNFα single positive CD4 T cells compared to latently infected individuals (Day, 
Abrahams et al. 2011) It is possible that the contrasting results could be due to 
differences in the patient cohorts used. Another group has also shown increased 
frequencies of polyfunctional and TNFα single-positive CD4 T cells in TB cases 
compared to exposed household contacts (Sutherland, Adetifa et al. 2009). In 
contrast, there has been relatively minimal research on CD8 T cells in this disease 
model, primarily because the method by which CD8 T cells recognize MTB antigens 
was a subject of speculation for some time (Orme 1987; Flory, Hubbard et al. 1992; 
Seder and Ahmed 2003; Chen, Huang et al. 2009). 
 
1.5.1 CD8 T cell responses in MTB infection 
 
Previous research on the role of CD8 T cells in combating MTB has involved both 
mouse and non-human primate models of infection. Van Pinxteren et al showed the 
importance of CD8 T cells in maintaining latency in a mouse model. Latency was 
established by treating aerosol-infected mice with anti-TB drugs in order to maintain 
a low bacterial load, and reactivation was simulated by removing the drug treatment. 
In vivo CD8 T cell depletion during the latent period resulted in a 10-fold increase in 
bacterial numbers, whereas CD4 T cell depletion produced more modest changes 
(van Pinxteren, Cassidy et al. 2000). It is important to note that murine studies are 
limited in their applicability to MTB infection in humans, as both the disease 
pathology and dose of infection differ (Mestas and Hughes 2004).  
Non-human primates are more relevant models of MTB infection, as 
approximately 50% of infected non-human primates establish latency and 50% 
develop active TB disease, with a disease course and pathology similar to that seen 
in humans (Chen, Huang et al. 2009). CD8 T cell depletion in rhesus macaques 












disease and in protecting against re-infection. BCG vaccinated macaques were 
depleted of CD8 T cells in vivo, and then challenged with MTB. Upon challenge, 
these macaques displayed reduced immunity to MTB compared to un-depleted 
controls. In a separate experiment, cured macaques were CD8-depleted and then 
re-infected with MTB. The CD8-depleted animals were significantly more likely to re-
develop TB disease compared to the un-depleted controls (Chen, Huang et al. 2009; 
Weerdenberg 2009). Although animal models are relevant and informative, it is ideal 
to perform studies using a human model of MTB infection. 
 
1.5.1.1 Antigen recognition and epitope specificity 
 
By virtue of the pathogen’s intracellular location, there is a clear-cut mechanism for 
CD4 T cell activation via MHC II antigen presentation. On the other hand, classical 
CD8 T cells recognize peptides presented by MHC I molecules. One of the theories 
that accounts for presentation of MTB antigens to CD8 T cells via MHC I (cross-
presentation) is the translocation of mycobacterial proteins from the phagolysosome 
of an APC to the cytosol, where proteosome-mediated degradation occurs, following 
transport to the endoplasmic reticulum and loading onto MHC I (Weerdenberg 2009). 
However, non-translocating mycobacteria such as BCG are also known to induce 
CD8 T cell mediated immunity (Weerdenberg 2009). Another theory for explaining 
cross-presentation involves apoptosis of the infected innate cell (Winau, Hegasy et 
al. 2005). During the apoptotic process the infected cell releases vesicles containing 
protein and lipid components of MTB, which are taken up by uninfected by-stander 
APCs and processed as intracellular components via the MHC I pathway (Schaible, 
Winau et al. 2003). 
In humans, CD8 T cells specific for MTB peptides have been identified using 
high throughput IFNγ release assays. In one publication, CD4-depleted cells were 
used to generate MTB-specific T cell lines from infected individuals (both latent and 
active disease). CD8 epitopes were identified using an IFNγ Elispot assay, which 
showed a greater frequency of responses to CFP10 peptides compared to ESAT6 
peptides (Lewinsohn, Winata et al. 2007). CFP10 responses were also more variable 












Because this study was not performed ex vivo, it was difficult to determine the in vivo 
frequency or magnitude of CD8 T cell responses to these peptides. Another study 
performed epitope mapping of ESAT6 in patients with active TB disease using short-
term cell lines, and found that the peptides corresponding to amino acids 69-76 and 
82-90 of ESAT6 were preferentially recognized (Lalvani, Brookes et al. 1998). A 
previous study has identified an immunodominant response in the C-terminus of 
CFP10 in two CD8 T cell clones from one donor (Lewinsohn, Zhu et al. 2001). 
 
1.5.1.2 Effector functions 
 
Many studies identify antigen-specific T cells by IFNγ production following antigen 
stimulation, hence its production in CD8 T cells is well characterized (Lalvani 2007). 
Upon encounter with antigen, both effector and central memory cells produce IFNγ 
and it is one of the last cytokines to stop being produced in the event of T cell 
exhaustion (Yi, Cox et al. 2010). Therefore IFNγ is an ideal marker of antigen 
specificity when studying cells that may have reduced function, such as chronically 
stimulated cells in TB disease. MTB-speci ic CD8 T cells have also been shown to 
produce TNFα and IL-2 (Sutherland, Adetifa et al. 2009). 
Mouse models of MTB infection have indicated an important role of cytotoxic 
molecules in control of infection. Mice deficient in the cytotoxic molecule perforin 
have reduced survival time upon exposure to MTB (Grotzke and Lewinsohn 2005). It 
has also been found that the lytic potential of CD8 T cells waned from early infection 
to chronic infection in mice (Lazarevic, Nolt et al. 2005). In humans, cytotoxic CD8 T 
cells preferentially lyse heavily MTB-infected APCs (Lewinsohn, Heinzel et al. 2003). 
This may have implications when comparing cytotoxicity in LTBI and TB disease, as 
latently infected individuals are thought to have a lower antigen load and hence 
would have fewer heavily infected APCs. It has also been suggested that cytotoxic 
CD8 T cells may serve a role in maintaining latent infection (Pathan, Wilkinson et al. 
2000). Indeed reduced perforin production was found in TB patients compared to 
healthy controls (Smith, Klein et al. 2000), and impaired granulysin and perforin co-
expression was found at the site of infection in patients with chronic pulmonary TB 














Although there is a growing body of research on the epitope specificity and effector 
functions of CD8 T cells in MTB infection, there is still very little published research 
on the phenotype of chronically stimulated MTB-specific CD8 T cells in infected 
individuals. Mouse studies on MTB have shown that antigen-specific memory CD8 T 
cells produce less cytotoxic molecules and cytokines than newly primed CD8 T cells, 
implying that disease persistence may be due to the low quality memory response 
(Einarsdottir, Lockhart et al. 2009). Research on the gene expression patterns in 
pulmonary and lymphoid tissue of macaques with severe TB has shown over-
expression of genes involved in inflammation such as chemoattractants and cytokine 
receptors, and molecules associated with immune dysfunction such as PD-1 and 
PD-L2 (Qiu, Huang et al. 2008). In human models it has been found that PD-1 is 
upregulated on antigen-specific lymphocytes in TB disease (Jurado, Alvarez et al. 
2008). In vitro blockade of PD-1 and its ligands increased the frequency of antigen-
specific IFNγ-producing CD8 T cells and enhanced degranulation (Jurado, Alvarez et 
al. 2008). Phenotypic analysis of CD8 T cells in the peripheral blood of children 
revealed that central memory cells were predominant in TB disease, and this 
population waned after therapy to give way to cytotoxic, cytokine producing effector 
cell populations (Caccamo, Meraviglia et al. 2006). The authors suggested that 
effector CD8 T cells might have been sequestered to the site of disease. Indeed, an 
increased frequency of effector memory and terminally differentiated CD8 T cells 
were found in the cerebrospinal fluid of a subject with TB meningitis (Caccamo, 
Meraviglia et al. 2006). Several CD8 cell markers have been identified in other 
chronic infection models, such as the aforementioned PD-1 molecule. CD95, Bcl-2, 
CD127, CD57 and Ki67 were used in this study as markers of activation, 
senescence and susceptibility to apoptosis of antigen-specific CD8 T cells.  
CD95, also known as Fas, is expressed on effector memory cells and to a lesser 
extent central memory cells. Naïve cells do not express it. Upon ligation with the Fas 
ligand (FasL), this receptor initiates a cascade of intracellular events that culminates 
in apoptosis; hence increased expression of CD95 on a cell surface suggests its 
susceptibility to apoptosis. Upon stimulation with FasL, CD95 mediates the form of 












Cells may also undergo apoptosis due to an activation dependent event that is 
initiated within a cell by an internal signal, as opposed to an external molecule. This 
is known as activated cell autonomous death (ACAD). Bcl-2 is an anti-apoptotic 
molecule, and its decreased expression on the mitochondrial membrane in a cell has 
been correlated to increased cell death via ACAD. A signaling cascade within the cell 
occurs when the levels of pro-apoptotic molecules on the mitochondrial membrane 
become greater than anti-apoptotic molecules (Krammer, Arnold et al. 2007). 
Effector memory cells express less Bcl-2 than their naïve and central memory 
counterparts. This indicates that effector memory cells are more sensitive to 
apoptosis (Schluns and Lefrancois 2003). 
Effector memory populations are sometimes defined by their increased 
expression of CD57 relative to central memory cells (Wood, Twigg et al. 2009). This 
is supportive of the use of CD57 as a marker for replicative senescence, as effector 
T cells have a lower proliferative capacity than central memory T cells. In a HIV 
disease model the expression of CD57 on CD8 T cells positively correlates with Fas 
and FasL expression (Wood, Twigg et al. 2009). Interestingly however, senescent 
cells have been shown to be resistant to apoptosis hence the accumulation of 
CD57+ cells in a long-term assay is hypothesized to be due to decreased death, not 
increased proliferation of this population (Wood, Twigg et al. 2009). Additionally, the 
frequency of CD57+ T cells is elevated in TB disease compared to healthy controls 
(Sada-Ovalle, Torre-Bouscoulet et al. 2006). The function of CD57 is yet to be 
determined, but it is known to bind human natural killer cell-1 (HNK-1), a 
glycopeptide found in cell adhesion molecules (Wood, Twigg et al. 2009). CD57 has 
been used to define antigen-specific IFNγ-producing cells with defects in proliferation 
(Brenchley, Karandikar et al. 2003). 
CD127 (the IL-7 receptor α chain) is a marker of long-lived memory cells with 
proliferative potential, and is required for the maintenance of a central memory pool 
(Cellerai, Perreau et al. 2010). Terminally differentiated CD4 T cells cells do not 
express CD127 (Lim and Kim 2007). Previous research on CD127 shows that it is 













Ki67 is a marker for proliferation and activation that is upregulated over several 
days of exposure to antigen. Cells in the G1, G2, S and mitosis phase of the cell cycle 
will express Ki67, but resting cells (G0) will not. Measurement of intracellular Ki67 
directly ex vivo will determine the in vivo frequency of Ki67+ cells without inducing de 
novo expression. Therefore a short term ex vivo assay can used to describe the 
frequency of circulating Ki67+ cells, whereas a long-term in vitro stimulation assay is 
used to detect Ki67 upregulation in proliferating, antigen-specific cells (Soares, 
Govender et al. 2010). 
 
1.6 Conclusion  
 
The evidence presented here indicates an important role for CD8 T cells in the 
immune response to MTB, and provides rationale for further analysis of these cells 
for a better understanding of MTB immunopathogenesis and to facilitate design of 
novel TB vaccines. It also suggests that CD8 T cell dysfunction or exhaustion may 
play a role in the progression from latency to active TB disease, for example CD8 
depletion in a mouse model of latency resulted in active TB disease (van Pinxteren, 
Cassidy et al. 2000), as did CD8 gene disruption (Turner, D'Souza et al. 2001). CD8 
depletion in a rhesus macaque model led to increased risk of re-infection (Chen, 
Huang et al. 2009). In this study, we have identified ESAT6 and CFP10 epitopes that 
were recognized by CD8 T cells, and described the phenotype of CD8 T cells in 
terms of markers of activation, memory and susceptibility to apoptosis. Ultimately the 
results from this study contribute towards a better understanding of the role of CD8 T 
cells in MTB infection, and allow for development of a platform for future studies to 
delineate associations between MTB-specific CD8 T cell function and disease 
progression using prospective, longitudinal cohorts sampled prior to and following 
development of TB disease. Such studies will aid in identifying immune correlates of 
protection against development of active TB disease, and open up new avenues of 














1.7 Current study: Aims and objectives  
 
Aim 1: 
Determine the breadth and specificity of MTB-specific CD8 T cell responses to 
ESAT6 and CFP10 peptides in individuals with latent and active TB disease. 
Hypothesis: The breadth and magnitude of the MTB-specific CD8 responses is 
associated with infection status and antigen load. High bacterial loads in individuals 
with active TB disease will generate a greater magnitude and breadth of MTB-
specific CD8 responses detectable in peripheral blood, compared to individuals with 
latent infection. 
Aim 2: 
Determine the phenotype of MTB-specific CD8 T cells associated with latent and 
active TB disease. 
Hypothesis: MTB-specific CD8 T cells in individuals with active TB disease will have 
increased expression of both activation and pro-apoptotic markers, and markers of 

























































































T cell epitopes are often identified using a high-throughput method in order to screen 
a large sample size rapidly and efficiently. Each method may identify a different 
parameter of antigen-specific cells, depending on the read-out of the assay. For 
example, the level of IFNγ production upon antigen stimulation can be used to 
determine the frequency of antigen-specific T cells. Epitopes can also be identified 
by proliferative capacity, cytotoxic capacity, or the production of other cytokines such 
as TNFα and IL-2. Ex vivo assays can give an indication of the in vivo frequency of T 
cell responses to various epitopes within peptides. In long-term assays, the in vivo 
magnitude of responses cannot be determined, as the antigen-specific cells have 
been expanded. To an extent, the parameter measured in an epitope-mapping assay 
will narrow the identification of antigen-specific T cells to certain subtypes. For 
example, ex vivo IFNγ assays will reveal the frequency of antigen-specific effector T 
cells, but not of naïve or anergic T cells. In this study, experiments were performed 
to identify subsets of cells that are present at very low frequencies in the blood. 
Hence in some instances, the population of antigen-specific cells was expanded via 
long-term stimulation for 6 days. In ex vivo Elispot assays, CD4 T cell depletion of 
peripheral blood mononuclear cells (PBMCs) facilitates identification of CD8 T cell 
responses in blood. In order to analyze antigen-specific T cell populations at a 
single-cell level, flow cytometry with fluorochrome-conjugated antibodies was used in 
long term and short term assays for phenotyping cells and identifying proliferating 



















2.0.1 Elispot assays 
 
An ex vivo IFNγ Elispot assay is a high throughput method for identifying the 
presence of antigen-specific T cells. The IFNγ Elispot assay is based on the premise 
that T cells secrete IFNγ when stimulated with their specific antigen. Wells of an 
Elispot plate are coated with a polyvinylidene difluoride (PVDF) membrane. This 
allows for high binding of the capture anti-human IFNγ primary antibody, which is 
incubated on the membrane. PBMCs and specific antigens are then incubated in 
each well. T cells exposed to immunogenic peptides will secrete IFNγ, and this 
cytokine will bind to the primary antibody. The cells and antigens are then washed 
away leaving the bound IFNγ, which is detected in a series of steps. First, a 
secondary biotinylated anti-human IFNγ antibody is added and it binds wherever 
IFNγ is present. A streptavidin-peroxidase conjugated complex is added and binds to 
the biotin. Substrate is then added and is altered by the peroxidase enzyme to form 
a blue precipitate at every location that IFNγ has bound. An Elispot plate reader 
detects these precipitates as spots, with  each spot representing one IFNγ-producing 
cell. The frequency of antigen-specific cells is then reported as the number of spot 
forming cells (SFC) per million PBMC.  
 
2.0.2 CD4 T cell depletion 
 
Because CD4 and CD8 T cells both produce IFNү, it is not possible to determine 
which cell type is responding to a given antigen in an Elispot assay. In order to 
identify specific peptides eliciting a CD8 T cell response, CD4 T cells were depleted 
prior to use in the IFNγ Elispot assays. This can be done using magnetic beads 
conjugated to an anti-CD4 antibody. These beads will cause the attraction of bead-
conjugated CD4 T cells towards a magnet in their proximity. CD4 T cells will 
aggregate on the side of the tube nearest to the magnet, effectively separating the T 
cells. The solution containing CD4-negative cells can then be extracted and used in 
further experiments. By removing CD4 T cells from samples, the relative proportion 
of CD8 T cells within the PBMC population is increased, resulting in an increased 
sensitivity to CD8 T cell cytokine production in CD4 T cell-depleted samples 












2.0.3 Intracellular cytokine staining and flow cytometry 
 
Intracellular cytokine staining (ICS) followed by flow cytometry is a popular method 
for characterizing antigen-specific T cells on a single cell basis. Cells are stained 
with fluorescently-conjugated antibodies. Flow cytometry employs a fluidics system 
that allows the sample to be ordered into a stream of single particles. As each 
particle travels, it passes through several beams of light causing the fluorescently-
conjugated antibody to become excited and fluorescence. Forward scatter (FSC) 
and side scatter (SSC) detectors will collect scattered light from each particle to 
provide information about the particles size and granularity respectively. 
Photomultiplier tubes amplify light emitted by the antibody conjugates, thus providing 
information about the antibodies bound to each cell. More than one type of 
fluorescently-conjugated antibody can be used to stain cells in multi-color flow 
cytometry. An LSRII flow cytometer was used in this study, which can detect up to 12 
different parameters in one sample. The wavelengths emitted by the fluorescent 
conjugates may overlap, which results in inaccurate measurements of the true 
emission of each antibody. Data analysis programs that calculate and subtract the 
interference of one fluorescence channel from another will compensate for spectral 
overlap. Some molecules such as CD3 and CD8 are found on the surface of T cells. 
However others such as Bcl-2 and Ki67 are found intracellularly. Certain buffers are 
used to fix cells and permeabilize cell walls in order to allow for fluorescently-
conjugated antibodies to traverse the cell membrane and bind to their target. 
 
2.0.4 Lymphocyte proliferation assay and flow cytometry 
 
There are various assays to measure proliferative capacity, including incorporation of 
synthetic nucleosides into replicating DNA, upregulation of cell cycle molecules such 
as Ki67, and dye dilution assays. Ki67 is a nuclear protein expressed in cells in the 
G1, S, G2 and mitosis, but not in resting cells in the G0 phase of the cell cycle 
(Gerdes 1990; Scholzen and Gerdes 2000). The use of a cell trace dye such as 
Oregon Green (OG: 2', 7’-difluorofluorescein; Invitrogen) is a more established 
method of conducting a proliferation assay. OG is initially a colorless compound that 












leading to the formation of fluorescent conjugates that can be detected using flow 
cytometry. As a cell replicates, the volume of intracellular dye is divided between the 
daughter cells in a step-wise dilution. Hence the number of division cycles 
undergone can be ascertained using flow cytometry by measuring loss of 
fluorescence. When excited, OG emits fluorescence over the range 475 to 700 
nanometers, peaking at 518 nanometers, which is detected as a green light (Lyons 
2000; Wallace, Tario et al. 2008). A proliferation assay is more sensitive than an ex 
vivo assay because cells are exposed to antigens for a longer period of time, thus 
expanding antigen-specific populations. Only the subsets of cells with proliferative 
capability will be identified as antigen-specific in this assay; i.e. central and effector 
memory cells. Naïve and terminally differentiated effector cells may not be identified.  
 
2.1 Materials and Methods 
 
2.1.1 Study participants 
 
Mycobacterium tuberculosis (MTB)-infected male and female adults were recruited 
as part of a larger study of MTB immunopathogenesis at the SATVI clinical trials site 
in Worcester, South Africa. A subset of this group was used in this study. Individuals 
with active pulmonary TB disease were sputum smear positive and/or culture 
positive for MTB, and had been treated with first line anti-TB drugs for less than one 
week at the time of sample collection. A subset of participants with TB disease was 
followed longitudinally, with additional blood samples obtained at 2 and 6 months 
following initiation of anti-TB treatment. Adults with latent MTB infection (LTBI) were 
defined as asymptomatic healthy adults with IFNγ-positive T cell responses to 
CFP10 and/or ESAT6 peptides in an 8-hour whole blood ICS assay, and no previous 
history of diagnosis or treatment of TB disease. All study subjects had no other 
chronic conditions or co-infections, and were not on any steroids or 
immunosuppressive medication. Peripheral blood samples were obtained from all 
subjects and used for isolation of PBMCs as previously described (Day, Abrahams et 












study, which was approved by the Human Research Ethics Committee of the 
University of Cape Town, and by the Western Cape Department of Health.  
 
2.1.2 Thawing and counting of peripheral blood mononuclear cells 
 
PBMCs were isolated from blood and cryopreserved as previously described (Day, 
Abrahams et al. 2011). Before use in assays, cryopreserved PBMCs were thawed in 
a 37oC water bath until a small ice chip was visible. 1ml of 10% FCS in RPMI (R10) 
containing DNase (Sigma-Aldrich; 0.01mg/ml) was immediately added to each 
cryovial in order to dilute the PBMCs. DNase is an enzyme that digests DNA, thus 
preventing live cells from becoming entangled and clumping in the DNA of lysed 
dead cells. The cells were transferred to 10ml of R10 containing DNase and 
centrifuged (456g, 10min). The supernatant was discarded and cells were washed in 
R10 (456g). Thawed PBMCs were counted in order to determine the number of 
viable cells. The cells were then counted as follows: PBS, an aliquot of PBMCs and 
Trypan blue were mixed together in an 8:1:1 dilution. Trypan blue is a negatively 
charged dye, hence it is repelled by the cell membrane of viable cells. It will enter 
cells with compromised cell membranes, indicating that they are not viable. 10µL of 
the dilution was loaded onto a Neubauer counting chamber. The number of cells 
present in two quadrants was averaged and divided by 10 to account for the dilution 
with PBS and Trypan blue. It was then multiplied by 1x106 to account for the original 




15-mer peptides overlapping by 10 amino acids (aa) were synthesized 
corresponding to the sequence of ESAT6 and CFP10; peptides were either used 
individually or pooled by protein. For the ex vivo IFNγ Elispot assays they were used 
at a final concentration of 2 µg/ml/peptide. For the ICS assays they were used at a 
final concentration of 1.25µg/ml/peptide and for the proliferation assay they were 
used at a final concentration of 0.1µg/ml/peptide. A CMV peptide pool (15-mers 












was used at the same concentrations as ESAT6 and CFP10 peptide pools for each 
assay. Staphylococcal enterotoxin B (SEB) was used as a positive control in the ex 
vivo IFNγ Elispot, the ICS and the proliferation assays at 1µg/ml, 1µg/ml and 
0.1µg/ml respectively. Individual peptides from ESAT6 and CFP10 were used at the 
same concentration as they were in the peptide pool for each assay.  
 
2.1.4 CD4 T cell depletion of PBMCs 
 
Cryopreserved PBMCs were thawed and counted as described in section 2.2.2. 
They were then washed in PBS (931g) and the supernatant discarded. They were 
suspended in PBS containing 0.5% bovine serum albumin (Sigma-Aldrich) and 2mM 
EDTA (Sigma Aldrich) at a concentration of 1x107 cells/ml. 50µL/ml of anti-human 
CD4 antibodies conjugated to magnetic beads (IMag; BD Biosciences) were added 
to the tubes and incubated at room temperature (RT) for 20-30 min. The tube was 
placed on a magnet and incubated for 8min at RT. CD4+ cells aggregated on the 
side of the tube nearest to the magnet, whereas CD4− cells remained in suspension. 
Without removing the tube from the magnet, supernatant was aspirated and 
transferred to a second tube. The tube on the magnet was replaced with the second 
tube, and incubated for 3min after which the aspiration and transfer of CD4− cells 
was repeated. After this process, the CD4-depleted PBMCs were counted using the 
method described in section 2.2.2. 
In order to assess the efficiency of the magnetic bead depletion, CD4-depleted 
samples were centrifuged (931g), and the supernatant discarded. The pellet was 
vortexed and the cells stained with fluorescently-conjugated anti-CD3 PE (SK7), anti-
CD4 FITC (SK3), and anti-CD8 APC (SK1) antibodies (all from BD Biosciences). The 
cells were incubated with antibodies for 1 hour at 4oC before they were washed in 
PBS (931g) and re-suspended in PBS prior to acquisition on a FACSCalibur flow 














2.1.5 Ex vivo IFNγ Elispot 
 
An IFNγ Elispot was performed in order to identify individual 15-mer peptides within 
ESAT6 and CFP10 that elicit a CD8 T cell response. 100µl/ well of 0.5 µg/ml anti-
human IFNγ antibody (MABTECH; 1-D1K) was added to a 96-well filtration plate 
(MILLIPORE) and incubated overnight at 4°C. The plate was then washed with 
1%FCS in PBS, before adding 90µl of R10 to each well and incubating for 2-4hours 
at 37oC in order to block non-specific binding to the primary antibody. Cryopreserved 
PBMCs were thawed and counted as described in section 2.2.2. CD4 cells were 
depleted as described in section 2.2.4. Depleted samples were counted and diluted 
in R10 at a concentration of 1x106 cells/ml before being rested for 6 hours at 37oC. 
100,000 cells were added to each well of the Elispot plate, followed immediately by 
the addition of antigens to the appropriate wells. The plate was incubated overnight 
at 37oC (15-18 hours) before being washed with PBS. 0.5µg/ml of biotinylated anti-
human-IFNγ antibody (MABTECH; 7-B6-1) was incubated in the wells for 90min at 
RT before being washed off with PBS. 0.5 µg/ml of streptavidin-conjugated alkaline-
phosphatase (MABTECH) was incubated in the wells for 40min at RT before being 
washed off. A substrate for alkaline phosphatase was added in the following pre-
mixed solution (MABTECH): 4% AP color buffer, 1% Buffer A, 1% Buffer B, in water 
and incubated on the plate for 15min at RT in the dark. Tap water was poured over 
the plate in order to terminate the reaction, and the plate was left to dry in the dark. 
The number of spots per well was determined using an Immunospot Elispot plate 
reader (AID).  
 
2.1.6 PBMC proliferation assay 
 
In order to identify which peptides elicited an immune response by T cells, 
cryopreserved PBMCs were stimulated with individual ESAT6 and CFP10 peptides 
in a 6-day proliferation assay as follows: thawed PBMCs were washed in PBS 
(931g). PBMCs were labeled with 0.5µg/ml of CellTrace™ Oregon Green® 488 
carboxylic acid diacetate, succinimidyl ester (OG; Invitrogen) in PBS. The tube was 
mixed by flicking, and left to incubate at RT for 3min. The tube was then vortexed for 












tube. After another 4min incubation, the tube was topped up to 10ml with PBS and 
centrifuged (456g); the supernatant was discarded. The cells were diluted in R10 to 
a concentration of 1.5x106 PBMCs/ml and plated onto a 96-well culture plate 
(300,000 cells/well). The plate was incubated at 37oC overnight. The next day, 
antigen was added to each well and the plate was placed in a 37oC 5% CO2 
incubator for 6 days. The 96-well plate was removed on day 6 and the contents of 
each well were transferred to FACS tubes and washed with 1ml PBS. The cells were 
centrifuged (931g), the supernatant was discarded and the cells incubated with violet 
viability dye (VIVID; LIVE/DEAD Fixable Violet Dead Cell Stain Kit, Molecular 
Probes, Invitrogen) for 20min. The cells were washed with PBS (931g) before an 
antibody cocktail containing anti-CD3 PerCP.Cy5.5 (SK7), anti-CD4 APC (SK3), and 
anti-CD8 PE (SK1), all from BD Biosciences, were added. The cells were incubated 
with antibodies for 1hr at 4oC in the dark. Unbound antibodies were washed off using 
PBS (931g). The supernatant was discarded and the cells were re-suspended in 
PBS for acquisition using an LSR II flow cytometer (BD Biosciences). 
 
2.1.7 Intracellular cytokine staining assay  
 
An intracellular cytokine staining (ICS) assay was used to phenotype CD8 T cells ex 
vivo. PBMCs were thawed using the protocol described in section 2.2.2. They were 
washed in R10 (931g), the supernatant was discarded, and the cells were rested for 
approximately 6hrs in R10 at 37oC. After resting, antigens were added to the tubes 
and they were incubated at 37oC for a total of 7hrs. Brefeldin A (10µg/ml; Sigma-
Aldrich) was added after the first 2hrs of the 7hr incubation in order to inhibit cytokine 
secretion. Cells were washed in PBS (931g) and the supernatant was discarded. 
They were incubated with VIVID for 15min at RT, followed by washing in PBS 
(931g). The supernatant was discarded and the cells were fixed (FACS Lysing 
solution; BD Biosciences), washed with PBS (931g), and permeabilized with 
Perm/Wash buffer (BD Biosciences) for 15min at RT. The cells were pelleted by 
centrifugation (931g) and the supernatant was discarded. Cells were stained at RT 
with the following fluorescently-conjugated monoclonal antibodies: anti-CD3 APC-H7 
(SK7), anti-CD8 QDot605 (3B5), anti-IFNγ Alexa Fluor 700 (B27), anti-Bcl2 FITC 












(HLR-7r-M21), and anti-CD95 PE Cy7 (DX2). After 1hr, unbound antibodies were 
washed off with Perm/Wash Buffer (931g), the supernatant was discarded and cells 
were suspended in PBS for acquisition on a flow cytometer. In order to optimize this 
assay, antibodies were titrated, and a fluorescence-minus-one experiment was 
performed using an LTBI PBMC sample. All antibodies were obtained from BD 
Biosciences except anti-CD8 QDot605 antibody from Invitrogen, and anti-CD95 PE 
Cy7 and anti-CD57 APC antibodies from BioLegend. 
 
 2.1.8 Flow cytometry analysis  
 
An LSRII (BD Biosciences) flow cytometer was used to acquire the ICS and 
proliferation assay data. Flow cytometric data was analyzed using FlowJo v9.2 (Tree 
Star, Ashland, OR). Single-stained anti-mouse Ig κ beads (BD Biosciences) were 
used to calculate compensation. Anti-CD3 Pacific Blue antibody was used to 
compensate for VIVID. In the proliferation assay, anti-CD4 FITC antibody was used 
to compensate for OG. A compensation matrix was generated using FlowJo.  
The gating strategy involved first gating out morphologically abnormal cells that 
were identified by their FSC-height vs. FSC-area properties in a singlet gate. 
Lymphocytes were then gated on by plotting FSC-height versus SSC-area. After 
these initial gates, the fluorescently-conjugated antibodies were used to further 
discriminate specific populations as shown in later chapters. For continuous markers, 
or markers in which gates could not be accurately placed, median fluorescence 
intensity (MFI) was used to gauge expression levels. Gate placement for various 
markers and for proliferated cells was determined using the unstimulated samples. 
For the ICS assay, IFNγ positive cells were gated on to define antigen-specific 
subpopulations. In longitudinal analyses, PBMCs from the same donor at different 
time points were processed concurrently. 
 
2.1.9 Data analysis 
  
For the IFNγ Elispot assays, the average number of spots in the unstimulated wells 












for background IFNγ production. A response was considered positive if it was greater 
than the median plus 3 times the median absolute deviation (MAD) of the 
unstimulated samples after background subtraction (53.3 SFU/million PBMCs). 
In the 6-day proliferation assay, the frequency of proliferating (OGlow) cells in 
the unstimulated sample was subtracted from the stimulated samples for each 
donor. In addition, acquisition of a minimum of 10,000 live T cells (CD3+Vividlow) in 
the unstimulated sample was required for analysis of flow cytometry data as this 
number accounted for over 97% of data from unstimulated samples acquired. Any 
samples that failed to elicit a positive response to SEB stimulation were excluded. A 
response was considered positive if it was greater than the median plus 2 times the 
MAD of the unstimulated samples after background subtraction (0.757%). 
When analyzing results from the ex vivo phenotyping assay performed in 
Chapter four, three criteria were employed to identify a positive antigen-specific 
response preceding phenotypic analysis of antigen-specific CD8 T cell populations: 
(1) The frequency of CD8+IFNү+ cells had to be more than double the frequency of 
CD8+IFNү+ cells in that individual’s unstimulated condition, (2) the IFNү+ population 
had to be greater than the median plus 2 times the MAD of CD8+IFNү+ cells from 
the unstimulated samples, (3) the cell count of CD8+IFNү+ cells had to be >20. 
These criteria were employed to ensure that each response was real. In stimulation 
conditions that did not meet all 3 criteria, information on the CD8+IFNγ+ subset was 
excluded.  
 
2.1.10 Statistical analysis 
 
When comparing responses between LTBI and TB donors, a two-tailed non-
parametric Mann-Whitney test was used. In the phenotypic analysis, a non-
parametric Wilcoxon matched pairs test was used to compare expression of 
phenotypic markers between different cell populations within the same donor. P 
values of p<0.05 were considered significant. Prism (v5.0) and Intercooled STATA 














Identification of immunodominant CFP10 and ESAT6-specific CD8 T cell 






















































BCG has variable efficacy against pulmonary TB, thus the development of a more 
effective vaccine against TB is a matter of urgency. Increasing evidence indicates a 
role for CD8 T cells in controlling chronic infections, hence novel TB vaccines may 
benefit from induction of CD8 T cell responses. A first step is the identification of 
immunodominant CD8 T cell epitopes from antigens that are associated with 
successful immune control of Mycobacterium tuberculosis (MTB) infection. The aim 
of this chapter was to identify peptides within CFP10 and ESAT6 that elicit a CD8 T 
cell response in MTB-infected individuals. The secondary aims were to compare the 
breadth and magnitude of MTB-specific CD8 T cell responses within these proteins 
between individuals with LTBI and TB disease, and also to identify specific CFP10 
and ESAT6 peptides that elicit proliferative CD4 T cell responses. Proliferation 
assays and ex vivo IFNγ Elispot assays were used to identify CD8 T cell responses 
to immunodominant peptides in CFP10 and ESAT6. Approximately 20% of LTBI 
donors responded to peptides C4 and C16 in CFP10, and to peptide E12 in ESAT6. 
CD8 T cells in individuals with TB exhibited poor proliferative capacity, compared 
with LTBI. CD8 T cells in LTBI donors recognized a significantly greater breadth of 
CFP10 peptides than TB donors, however there was no difference between LTBI 
and TB in the breadth of recognition to ESAT6 peptides. MTB-specific CD4 T cells 
from LTBI donors exhibited greater proliferative capacity than TB donors, and 
recognized a greater breadth of peptides. Peptide mapping using an ex vivo Elispot 
assay identified IFNγ-producing CD8 T cell responses in 9/18 TB donors and 2/7 
LTBI donors. Together these data suggest that differential recognition of CFP10 
regions by CD8 T cells may distinguish between LTBI and TB disease, as CD8 T 
cells from LTBI donors responded to peptides in the N and C termini whereas TB 
donors responded to the C terminus. In addition, these results suggest differential 
functional capacities of MTB-specific CD8 T cells in latent and active TB disease. 
This is relevant for vaccine design as the response present in latently infected 















The currently licensed vaccine against TB, BCG, has a varying efficacy and a low 
level of protection against pulmonary TB (Hussey, Hawkridge et al. 2007). BCG is a 
live attenuated bacterium, hence its administration as a vaccine poses a risk of 
disseminated BCG in immune-compromised individuals (Hesseling, Cotton et al. 
2007). BCG was discovered and developed before 1920 and it has been in use since 
then. However, TB remains a global health problem, hence it is important to design a 
more effective vaccine.  
There must be a scientific basis behind the design and implementation of a 
new TB vaccine. According to Hussey et al, the ideal TB vaccine should be 
affordable, cost-effective and suitable for all ages. It should be safe and 
immunogenic in individuals that have been vaccinated with BCG or previously 
exposed to TB, as well as in immune-compromised individuals (Hussey, Hawkridge 
et al. 2007). From an immunological perspective, the vaccine should elicit a 
response that is associated with protection. This is challenging because the immune 
correlates of protection against TB have not yet been identified. A T cell response 
that is capable of multiple effector functions (‘polyfunctional’) may or may not be 
important, as the link between polyfunctionality and protection is unclear (Abel, 
Tameris et al. 2010). TB vaccines in development incorporate specific proteins that 
are known to be immunogenic to T cells, for example the novel TB vaccine candidate 
AERAS 402 contains Ag85A, Ag85B, and TB10.4 and elicits robust responses in 
both CD4 and CD8 T cells (Abel, Tameris et al. 2010). In order to identify 
immunodominant epitopes within a protein, fine mapping of its sequence is 
performed and the minimal sequence to elicit an immunodominant response may be 
incorporated into novel vaccines. ESAT6 and CFP10 are highly immunodominant 
MTB proteins (Millington, Fortune et al. 2011) for which T cell epitope mapping has 
been performed. 
CFP10 (culture filtrate protein-10) and ESAT6 (early secretory antigenic 
target-6) are highly conserved pathogenic factors secreted by MTB. They are 100 
and 95 amino acids long, respectively. Their expression is co-regulated within the 
bacteria (Renshaw, Lightbody et al. 2005), and upon expression they form a 












surface of macrophages and is thought to modulate host behavior (Renshaw, 
Lightbody et al. 2005). The RD1 locus containing ESAT6 and CFP10 has been 
deleted from BCG; therefore, they can be used to distinguish between an immune 
response induced by BCG vaccination versus MTB infection. 
Previous studies identifying CD8 T cell epitopes within CFP10 have employed 
the generation of antigen-specific T cell lines, in some cases through clonal 
expansion in vitro. Lewinsohn et al generated CD8 T cell clones from an 
asymptomatic LTBI donor. These T cell clones were stimulated with various peptides 
from ESAT6 or CFP10. IFNγ was produced in response to an epitope within the 
carboxyl (C) terminus of CFP10, accounting for the majority of IFNү production upon 
stimulation with the full protein (Lewinsohn, Zhu et al. 2001). In another study, 
Shams et al identified two epitopes within a 15-mer peptide corresponding to aa 71 - 
85 of CFP10. One epitope elicited a CD4 T cell response and the other epitope 
elicited a CD8 T cell response in asymptomatic TST-positive TB contacts. 
Stimulation with these epitopes caused IFNγ production as measured by a cultured 
Elispot, and cytotoxic activity in a chromium release assay (Shams, Klucar et al. 
2004). The epitopes detailed in the literature correspond to the amino (N) and C 
terminus of CFP10.  
Epitopes within ESAT6 have been identified using similar methods. For 
example, in a study by Lalvani et al, ESAT6 peptides that were predicted to bind to 
HLA class I molecules and be recognized by CD8 T cells were synthesized. When 
used to stimulate CD8 T cell lines from one donor with TB disease, two 
immunodominant peptides were found, each restricted by different HLA types. As 
well as IFNү production, these cells showed cytolytic activity (Lalvani, Brookes et al. 
1998). Another ESAT6 immunodominant peptide was identified in an asymptomatic 
MTB-infected donor using an ex vivo Elispot assay. This 9 aa sequence was HLA-
A68.02-restricted, and elicited a highly focused cytotoxic response (Pathan, 
Wilkinson et al. 2000). 
The information above is pertinent to CD8 T cell responses, however the 
majority of studies identifying MTB-specific T cell responses have not distinguished 
between CD4 and CD8 T cell responses. For example, CFP10 and ESAT6 peptide 












cohort of TB diseased and asymptomatic MTB-infected Zambian adults using an ex 
vivo IFNγ Elispot assay. It was found that every peptide was recognized by the T 
cells of at least one TB patient and one asymptomatic adult, from both CFP10 and 
ESAT6. A response in the C terminus of CFP10 was emphasized (Chapman, 
Munkanta et al. 2002). Another study using an ex vivo IFNγ Elispot assay by Lalvani 
et al found broad T cell recognition to ESAT6 in patients with TB and their household 
contacts (Lalvani, Nagvenkar et al. 2001). 
It has been shown in mice and cattle studies that the activation of T cells that 
produce IFNγ only does not correlate with protection (Mittrucker, Steinhoff et al. 
2007). Therefore, ex vivo Elispot assays alone may be insufficient to identify peptide 
responses that correlate with protection. Although it has not been proven in a TB 
disease model, memory T cells are hypothesized to be important in vaccine design. 
A hallmark of memory subsets is proliferative capacity. In previous research T cells 
have been expanded by stimulation with ESAT6 in a proliferation assay. After 
incubation with one of eight peptides spanning ESAT6, varied responses to 
sequences along the protein were found, implying that there are indeed differences 
in immunogenicity along the protein. The assay employed thymidine incorporation to 
determine the level of proliferation (Mustafa, Shaban et al. 2003), however another 
effective method involves cytosolic fluorescent dye dilution to identify cells that have 
proliferated. Together this information suggests that proliferative capacity provides 
another important measurement of immunogenicity in MTB infection. 
In summary, previous research identifying MTB-specific CD8 T cell responses 
generally employed small sample sizes and were highly specific to other countries 
and populations due to HLA restriction. In the South African population it is possible 
that there is differential peptide recognition compared with previously reported 
studies, due to different HLA types predominant in this population. This chapter 
compares T cell responses within individuals with newly diagnosed TB to latently 
infected individuals in a TB endemic area, using relevant measurements of immune 














3.2 Results  
 
3.2.1 Participant characteristics 
 
A total of 54 MTB-infected male and female adults were recruited for these studies at 
the SATVI clinical trials site in Worcester, South Africa. Individuals with active 
pulmonary TB disease were sputum smear positive and/or culture positive for MTB, 
and had been treated with first line anti-TB drugs for less than one week. Individuals 
with latent MTB infection (LTBI) were defined as asymptomatic healthy adults with 
IFNγ-positive responses to CFP10 and/or ESAT6 antigens in an 8hr whole blood 
intracellular cytokine staining (ICS) assay (data not shown), and no previous history 
of diagnosis or treatment of TB disease. Participant characteristics are shown in 
Table 3.1.  
 
Table 3.1. Participant characteristics. 
 
a  p <0.0001 compared with LTBI 
b Values denote mean (range)  
c p =0.0011, compared with LTBI 





















3.2.2 Flow cytometric analysis of a PBMC-based dye dilution proliferation assay 
 
An Oregon Green (OG) dye dilution assay is a means to identify the proliferation of 
lymphocytes after stimulation with antigen for several days in vitro. In order to 
identify immunodominant CD8 T cell epitopes targeted in MTB infection, a 6-day OG 
proliferation assay was used to identify individual peptides in CFP10 and ESAT6 that 
elicit a proliferative CD8 T cell response in 19 TB diseased and 20 LTBI donors. The 
sequential gating strategy used is shown in Figure 3.1A. PBMCs were stimulated 
with CFP10, ESAT6, and CMV pp65 peptide pools, as well as individual overlapping 
15-mer peptides spanning the entire length of CFP10 and ESAT6. All donors had a 















Figure 3.1. Flow cytometry gating strategy and representative data from the PBMC-based dye 
dilution proliferation assay. (A) A time gate was used to identify any abnormalities in fluorescence. 
Cells are gated on singlets and lymphocytes based on FSC-H and SSC-H characteristics. Live T cells 
(VividlowCD3+) were then gated on, followed by gating on CD4+ and CD8+ populations. (B) 
Representative flow plots of proliferating CD8 and CD4 T cell responses from an LTBI donor. No 
stimulation, stimulation with ESAT6 peptide pool, peptide E12, and SEB respectively are shown. (C) 
Representative flow plots of proliferating CD8 and CD4 T cell responses from a TB donor. No 


















































3.2.3 Individuals with LTBI display greater breadth and magnitude of MTB-specific 
proliferative CD8 T cell responses, compared to patients with TB 
 
The magnitude of CD8 T cell proliferative responses was compared between 
individuals with LTBI and TB. Representative flow cytometry data of T cell 
proliferation by LTBI and TB donors are shown in Figure 3.1B, C. LTBI individuals 
had higher frequencies of proliferating CD8 T cells to CFP10 and ESAT6 peptide 
pools and SEB, compared to TB diseased donors (Figure 3.2). We next mapped 
immunodominant peptides eliciting CD8 T cell proliferative responses in these two 
groups. We found that CD8 T cells from LTBI donors recognized a greater breadth of 
CFP10 peptides than TB donors; however, CD8 T cell proliferative responses to 
ESAT6 peptides were similar in breadth between the two groups (Figure 3.3). 
 
  
Figure 3.2. Reduced proliferative capacity of CD8 T cells in individuals with TB, compared with 
LTBI. The frequency of proliferating (OGlow) CD8 T cells upon stimulation for 6 days with CFP10 or 
ESAT6 peptide pools, or SEB is shown for LTBI (n=21) and TB (n=19) donors. Results are shown 
after subtraction of background proliferation in the negative control sample. Horizontal lines represent 



























p  =0.0001 p  =0.0317 p  =0.0001













Figure 3.3. Greater breadth of proliferative CD8 T cell responses to CFP10 peptides in 
individuals with LTBI, compared to patients with TB. Individual 15-mer overlapping peptides 
spanning the sequence of CFP10 (left panel) and ESAT6 (right panel) were used to stimulate PBMCs 
from donors with LTBI (n=21) and TB (n=19) in a 6-day proliferation assay. The number of peptides 
eliciting a positive proliferative CD8 T cell response for each donor is shown. Horizontal lines 
represent the median number of peptides recognized by each individual. Statistical differences were 
assessed by the Mann Whitney test.  
 
Individual 15-mer peptides from ESAT6 and CFP10 elicited CD8 T cell proliferation 
in approximately half of MTB-infected d nors. Peptides C4 and C16 in CFP10, and 
peptide E12 in ESAT6, elicited a response in over 20% of LTBI donors. Interestingly, 
we were unable to detect proliferative CD8 T cell responses to E12 in any of the TB 
donors. It is noteworthy that specific peptides eliciting a proliferative response in TB 
donors were not concentrated in any particular region of CFP10 or ESAT6 in this 
assay (Figure 3.4). Overall these results show that LTBI donors have an overall 
increased proliferative capacity, and a greater breadth of recognition of CFP10 




























































Figure 3.4. Frequency of recognition of individual 15-mer peptides in CFP10 and ESAT6 by 
CD8 T cells. PBMCs were incubated with individual overlapping 15-mer peptides from CFP10 (A) or 
ESAT6 (B) in a 6-day proliferation assay as described in Figure 3.3. The percentage of TB (n=19) and 
LTBI (n=21) donors who had a positive proliferative CD8 T cell response to each peptide is shown. 
 
3.2.4 Identification of CFP10 and ESAT6-specific CD8 T cell responses by an ex 
vivo IFNγ Elispot assay 
 
Individuals with TB generally displayed poor proliferation in the 6-day proliferation 
assay, compared with LTBI individuals. Hence assessment of proliferative capacity 
alone as a marker for antigen specificity may preclude the identification of antigen-
specific T cells with effector functions other than proliferation. An ex vivo IFNγ Elispot 
assay was therefore used to identify CD8 T cell responses in TB as well as LTBI 
donors. In order to identify MTB-specific CD8 T cell responses, CD4 T cells were 
depleted from PBMCs using magnetic beads conjugated to anti-CD4 antibodies prior 
to use in the Elispot assay. The level of depletion was assessed in 15 donors by 
LTBI
TB






















































comparing pre-depletion and post-depletion CD4 T cell frequencies by flow 
cytometry. Representative flow cytometry data pre and post CD4 T cell depletion are 
shown in Figure 3.5A. Over 99% of CD4 cells present in PBMCs were depleted, as 
shown in Figure 3.5B, C.  
 
 
Figure 3.5. Flow cytometric analysis of CD4 T cell depletion efficiency with magnetic bead-
conjugated antibodies. Cryopreserved PBMCs were thawed and incubated with magnetic bead-
conjugated anti-CD4 antibodies. (A) Representative flow plots of a PBMC sample prior to CD4 T cell 
depletion (top row), and the same sample post-depletion (bottom row). Cells were gated on 
lymphocytes, followed by CD3 T cells, and then CD4 and CD8 cells. (B) The frequency of CD4 T cells 
pre- and post-depletion. (C) Summary data of efficiency of CD4 T cell depletion. Bars correspond to 
































































Following CD4 T cell depletion, PBMCs from 18 TB donors were stimulated with 
either CFP10 or ESAT6 individual peptides in an overnight IFNγ Elispot assay. All 18 
donors were also stimulated with CFP10 and ESAT6 peptide pools in this assay. 11 
donors responded to ESAT6 or CFP10 peptide pools, and 9 of the 11 responders 
had a detectable CD8 T cell response to one or more individual peptides in the 
Elispot assay. Only 2/7 LTBI donors had ex vivo CD8 T cell responses above the 
cutoff to CFP10 or ESAT6 peptide pools, indicating MTB-specific CD8 T cells are 
present in very low frequencies in peripheral blood during latent infection. 
Representative Elispot assay data from a TB diseased individual with a CD8 T cell 
response to CFP10 are shown in Figure 3.6A; representative data from an LTBI 
donor are shown in Figure 3.6B. Figure 3.6C shows the SFU/million CD4-depleted 













Figure 3.6 Detection of CFP10 and ESAT6-specific CD8 T cell responses in individuals with TB 
using an IFNγ Elispot assay with CD4-depleted PBMCs. CD4-depleted PBMC from donors with TB 
disease (A) or LTBI (B) was stimulated with individual overlapping 15-mer peptides or CFP10 and 
ESAT6 peptide pools in an overnight IFNγ Elispot assay; representative images of individual wells are 
shown. Unstimulated and SEB wells were done in duplicate or triplicate. 200,000 CD4-depleted 
PBMC were added to each well. (C) Background subtracted numbers of spot forming units (SFU) per 






































































































































































































































































Figure 3.7. Identification of CD8 T cell responses to individual CFP10 and ESAT6 15-mer 
peptides in individuals with LTBI and TB by ex vivo IFNγ production. CD4-depleted PBMCs were 
used in an Elispot assay as described in Figure 3.6. The number of spot forming units (SFU) per 
million CD4-depleted PBMCs is shown for each peptide. Results are shown after subtraction of 
background cytokine production in the negative control wells. Each graph represents one donor. 
 












































































































































































Nine TB disease donors were tested with individual CFP10 15-mer peptides using an 
Elispot assay with CD4-depleted PBMCs, and 5/9 donors had a positive response. 
Out of these responders, 4/5 produced IFNγ when stimulated with peptides from the 
C-terminus of CFP10 (i.e. C15 to C18), whereas one responder only responded to 
peptide C7. The immunodominant response in the only LTBI responder to CFP10 in 
an Elispot assay was to peptide C11. There were no positive CD8 T cell responses 
detected to peptides in the N-terminus of CFP10 (i.e. C1 to C5). Although every 
responder displayed immunodominant recognition of one peptide, the peptide 
recognized differed across donors (Figure 3.7). Four out of nine TB donors had a 
CD8 T cell response to ESAT6 peptides in an ex vivo CD4 depleted Elispot. The 
differences in magnitude of response within these donors can be attributed to inter-
individual variation in immune activity. The differences in peptide recognition within 
these donors may be due to varied HLA types present in this population. However 
this is speculative, as the donors were not HLA-typed.  
Tables 3.2 and 3.3 summarize the immunogenic CFP10 and ESAT6 peptides 
eliciting a CD8 T cell response in either the 6-day proliferation assay or the ex vivo 
CD4-depleted IFNγ Elispot assay. In Table 3.2, peptides that elicited a response in 
CFP10 (top section) or ESAT6 (bottom section) in more than two of the 40 MTB-
infected donors that were tested are shown. Table 3.3 shows any peptide eliciting a 
response above the cutoff after background subtraction in the TB (n = 18) and LTBI 



















Table 3.2. Immunodominant 15-mer peptides in CFP10 and ESAT6 eliciting proliferative CD8 T 
cell responses in MTB infected donors.  
 




















C4 !"#$%&'!()*+,&(- 16 - 30 6 (15%) 1.03% 
C5 &'!()*+,&(,.$'+- 21 - 35 4 (10%) 1.00% 
C8 /!'),!,0%!//!+/- 36 - 50 3 (7.5%) 1.29% 
C15 $&'+"&%,/!.,1'%- 71 - 85 4 (10%) 1.63% 
C16 &%,/!.,1'%-/($$,- 76 - 90 5 (12.5%) 3.63% 
E2 0"#/!&$///'/&,!- 6 - 20 3 (7.5%) 1.21% 
E6 2'))($!*,')+*)/- 26 - 40 3 (7.5%) 2.16% 
E7 $!*,')+*)///0!!- 31 – 45 3 (7.5%) 3.68% 
E12 ,*0(/+/+$)""/),-- 56 - 70 4 (10%) 1.93% 












Table 3.3. Immunogenic CFP10 and ESAT6 peptides eliciting CD8 T cell responses in MTB  
infected donors in the ex vivo IFNγ Elispot assay.  
 
a  The number of donors responding a given peptide divided by the number of donors tested for that 
specified peptide. 
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We were able to perform both the proliferation and Elispot assays on 7 TB donors 
and 3 LTBI donors (Table 3.4). The same peptide specificities were not identified in 
both assays in any of the donors, suggesting populations of MTB-specific CD8 T 
cells with different epitope specificities may be associated with different effector 
functions. Taken together, these data indicate that MTB-specific IFNγ-producing 
CD8 T cells that lack proliferative capacity are present in individuals with TB, and 
that CFP10 and ESAT6-specific CD8 T cells may be present at very low frequencies 
in peripheral blood of LTBI individuals, but maintain robust proliferative capacity 
upon stimulation for several days in vitro.  
 
Table 3.4. Comparison of individual CD8 T cell responses from MTB infected donors identified 
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3.2.5 Increased breadth and magnitude of MTB-specific proliferative CD4 T cell 
responses in LTBI, compared with TB donors 
 
The above results indicate CD8 T cell proliferation is impaired in individuals with TB, 
compared with LTBI. To begin to address whether there was also evidence of 
differential proliferative capacity of CD4 T cells in LTBI and TB donors, CD4 T cell 
proliferation was analyzed in the OG-based proliferation assay described above. The 
information gathered from this subset was used to create a CD4 T cell peptide map 
for CFP10 and ESAT6. For TB donors, only one donor responded to any given 
peptide, whereas an immunodominant CFP10 peptide, C16, elicited a response from 
6/20 LTBI donors (Figure 3.8A). Four ESAT6 peptides (E6, E12, E13, and E15) 
elicited a proliferative CD4 T cell response in 4/20 LTBI donors (Figure 3.8B). Apart 
from peptide E17, each peptide was recognized by CD4 T cells from at least one 
LTBI donor, thus indicating the broad level of immunogenicity for both of these 
proteins. Similar to CD8 T cells, CD4 T cells from LTBI donors proliferated to a 
greater breadth of ESAT6 and CFP10 peptides overall than CD4 T cells from TB 
donors (Figure 3.9A). The magnitude of MTB-specific proliferating CD4 T cells was 
also greater in LTBI donors (Figure 3.9B). Overall, the results indicate that CD4 T 
cells in LTBI have an increased magnitude of proliferation compared to TB disease, 














Figure 3.8. Frequency of recognition of individual 15-mer peptides in CFP10 and ESAT6 by 
CD4 T cells. PBMCs were incubated with individual overlapping 15-mer peptides from CFP10 (A) or 
ESAT6 (B) in a 6-day proliferation assay. The percentage of TB (n=19) and LTBI (n=20) donors who 
had a positive proliferative CD4 T cell response to each peptide is shown. Differences in the 
frequency of recognition of individual peptides between LTBI and TB donors were assessed using the 
Fisher’s exact test. 
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Figure 3.9. Greater breadth and magnitude of proliferative CD4 T cell responses in individuals 
with LTBI, compared to patients with TB. Individual overlapping peptides spanning the sequence of 
CFP10 and ESAT6, or CFP10 or ESAT6 peptide pools, were used to stimulate PBMCs from donors 
with LTBI (n=20) and TB (n=19) in a 6-day proliferation assay. (A) The number of peptides with a 
positive proliferative response for each donor is shown. (B) The frequency of proliferating (OGlow) CD4 
T cells after background subtraction is shown. Cells were stimulated with CFP10 and ESAT6 peptide 
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Correlates of protection need to be identified in order for rational vaccine design. In 
MTB infection, identification of immune correlates of protection is based in part on 
the assumption that latently infected individuals have managed to control infection 
more successfully than individuals who progress to develop active TB disease. 
Therefore, factors identified in individuals with LTBI but not TB may correlate with 
protection against development of TB disease. Such factors include the phenotype 
and functional capacity of antigen-specific T cells, for example memory cell 
phenotype, cytotoxicity, proliferative capacity, and cytokine production. In this study, 
we found that CD8 T cells from TB donors exhibited impaired proliferative capacity 
compared with LTBI upon stimulation with MTB-specific proteins and SEB. It is 
hypothesized that reduced proliferation in individuals with TB upon SEB stimulation 
may be due to the previous exposure of these cells to an altered microenvironment 
that was caused by TB disease. Differential epitope specificity was also observed in 
the proliferation assay, with CD8 T cells from LTBI donors targeting different 
peptides than TB donors, for example E12 was recognized by CD8 T cells from LTBI 
donors and not TB disease donors. Moreover, LTBI donors had proliferative CD8 T 
cell responses to a greater breadth of peptides than TB disease donors. A 
decreased breadth and magnitude of CD4 T cell proliferative responses was also 
seen in individuals with TB, compared with LTBI. 
Antigen-specific CD8 T cells that produce cytokines but lack proliferative 
capacity are likely to be effector cells. These may be terminally differentiated fully 
functional cells, or terminally differentiated exhausted cells with reduced functionality, 
including reduced cytokine production and proliferation. Decreased PBMC 
proliferative capacity to CFP10 and ESAT6 peptide pools in individuals with TB 
disease, compared with LTBI, has been previously reported (Govender, Abel et al. 
2010). The increased magnitude of proliferation in LTBI donors in the presence of 
low levels of ex vivo IFNγ production in CD8 T cells implies a central memory 
phenotype of these cells. However a limitation of these data is that specific memory 
markers were not evaluated, hence classification into memory subsets was not 
possible. Due to the lack of proliferative capacity upon stimulation, it is thought that 












be noted that the ex vivo frequency of MTB-specific CD8 T cells is low in LTBI 
donors, as measured by whole blood ICS assays with CFP10 and ESAT6 peptide 
pools (data not shown), but increases after a 6-day culture in vitro. The IFNγ 
production by CD8 T cells of TB donors in the absence of proliferation suggests that 
the phenotype of CD8 T cells in individuals with TB differs from that of LTBI.  
A possible confounding factor that may contribute to differences in 
proliferation between the two groups is reduced viability in the TB donors after in 
vitro culture. However, T cell viability as measured by the frequency of VIVIDlow 
CD3+ cells after 6 days was similar in TB and LTBI donors (data not shown), 
suggesting that cell death in the assay system was not solely responsible for the 
decreased proliferation seen in TB donors.  
We have shown that CD8 T cells in individuals with TB produce IFNγ upon short-
term stimulation, but have a reduced proliferative capacity. IFNγ production is one of 
the last functions to cease in the event of T cell exhaustion, which results in 
dysfunctional T cell responses under conditions of high levels of persistent antigen 
stimulation (Wherry 2011). The reduced T cell proliferative capacity in the context of 
TB disease implies that MTB-specific CD8 T cells from these individuals may be 
functionally impaired. As the mycobacterial antigen load is greater in TB disease 
than LTBI, we initially hypothesized that high levels of antigen exposure would result 
in a greater breadth of recognition of CD8 T cell epitopes in the context of active TB 
disease compared with LTBI. Contrary to this hypothesis, there was a decreased 
breadth of recognition of CFP10 and ESAT6 epitopes among TB disease donors, as 
measured in the 6-day proliferation assay using cells isolated from peripheral blood. 
This is further evidence supporting the theory that CD8 T cells in TB disease are 
exhausted. However, it must be noted that MTB-specific CD8 T cells in TB disease 
may be trafficking to the site of disease in the lung, and therefore CD8 cells in the 
blood may not reflect the true breadth of responses present in these individuals.  
The CFP10 peptides identified in this study correspond with previous data 
indicating the immunogenicity of the C-terminus region of this protein and its 
importance in cell surface binding (Renshaw, Lightbody et al. 2005). The 71-85th aa 
position of CFP10 has been found to contain two epitopes by Shams et al (Shams, 












76-85, so it is found in both C15 and C16 sequences used in this study. T6 
corresponds to aa 71-79, so it is contained solely in C15. We found that peptides 
C15 and C16 were recognized by both CD4 and CD8 T cells in LTBI individuals. 
Lewinsohn et al used T cell clones to identify another CFP10 epitope corresponding 
to aa 2-11 (Lewinsohn, Zhu et al. 2001). We did not identify any MTB-infected donors 
in our study responding to this sequence in CFP10, possibly due to the small sample 
size or differential expression of particular MHC alleles between the two study 
populations.  
We found that ESAT6 peptides were widely recognized across the protein by T 
cells in individuals with LTBI and TB disease, consistent with previous studies 
(Chapman, Munkanta et al. 2002). For example, it has been shown by Lalvani et al 
that aa 69-76 of ESAT6 is immunodominant in a donor with active TB disease 
(Lalvani, Brookes et al. 1998). These peptide-specific cells displayed cytolytic activity 
and produced IFNγ. This sequence is within peptide E14, which induced IFNγ 
production ex vivo in TB donors, but not proliferation in the assays performed in this 
study. Lalvani et al also identified aa 82–90 as immunogenic (Lalvani, Brookes et al. 
1998); this sequence is found within E15, which was identified in the proliferation 
assay but not in the IFNγ assay as immunogenic. A minimal epitope corresponding 
to aa 21–29 of ESAT6 was found in an ex vivo Elispot (Pathan, Wilkinson et al. 
2000). It corresponds to a sequence within E4, which was identified in this study as 
immunodominant in one TB donor, also within the ex vivo Elispot assay. 
We were able to perform both the ex vivo Elispot and the proliferation assays in 
7 TB donors and 3 LTBI donors. It was very interesting to note that donors with a 
response to individual peptides in the proliferation assay did not have a response to 
the same peptides or the corresponding peptide pool in the Elispot assay. This was 
reciprocal, as responses in the Elispot assay were not found in the proliferation 
assay within individual donors. This strongly suggests that cytokine production and 
proliferative capacity represent distinct populations of antigen-specific CD8 T cells in 
MTB infection, and that the relative dominance of these functionally distinct 
populations may be associated mycobacterial antigen load and MTB 
infection/disease status. It must be mentioned that the extent to which CD4 T 
depletion influenced CD8 T cell responses to peptide stimulation in this short term 












and co-stimulation to CD8 T cells; hence their depletion may affect CD8 T cell 
recognition in the epitope mapping data. However we were still able to detect IFNү 
production from CD8 T cells in response to stimulation with the 15mer peptides. A 
potential reason why CD4 T cell proliferation was greater in magnitude than CD8 
proliferation may be that TB is an intracellular pathogen of macrophages, thus 
antigens are preferentially processed and presented by MHC II molecules. Hence 
CD4 T cells are the dominant response induced by MTB. 
It is important to note the geographical differences in study populations between 
previous studies and this study, as HLA restrictions identified in North American and 
European cohorts may not be prominent in the South African population. Because 
we did not HLA type donors in this study, it was not possible to define the HLA 
restriction and minimal epitopes for these peptides. Another limitation of this study 
was that only IFNγ production and proliferation were used as markers of antigen 
specificity. As a result, antigen-specific CD8 T cells secreting other cytokines or with 
cytotoxic activity may be missed. Antigen-specific CD8 T cells commonly produce 
IFNγ in conjunction with other cytokines, and it is one of the last cytokines to stop 
being produced in the event of exhaustion. Additional limitations of this study include 
the small sample size and inter-individual variation in background cytokine 
production and proliferation. Furthermore, it is possible that NK or NKT cells may 
produce IFNγ in the Elispot assay, however results from whole blood ex vivo ICS 
assays indicate that CD4- and CD8-negative cells do not produce significant 
amounts of IFNγ upon stimulation with CFP10 and ESAT6 peptides (data not 
shown).  
While low frequencies of IFNγ+ CD8 T cells are present in LTBI, they proliferate 
robustly upon stimulation in vitro. This suggests that the antigen specific cells in LTBI 
may have a central memory phenotype. This indicates that the in vivo environment in 
latently infected individuals may contain low levels of exposure to MTB antigens 
hence the antigen specific CD8 T cells are not chronically exposed to antigen. 
Because of this, the cells are not stimulated to become effector CD8 T cells, and 
instead maintain a long-term memory phenotype that is capable of robust 












Overall these results highlight the need to further define factors contributing to 
the functional differences observed in MTB-specific CD8 T cell responses between 
individuals with LTBI and TB. In the next chapter the phenotype of antigen-specific 
CD8 T cells in individuals with TB were compared to LTBI donors in order to further 
characterize MTB-specific CD8 T cell responses that are associated with either 
































Phenotypic characterization of Mycobacterium tuberculosis-specific CD8 T 











































In the previous chapter, we observed that some MTB-specific CD8 T cells from 
individuals with TB disease produced detectable levels of IFNγ ex vivo, but lacked 
robust proliferative capacity, whereas the opposite was true of MTB-specific CD8 T 
cells from healthy individuals with latent MTB infection (LTBI). It is important to 
determine the phenotypes of MTB-specific CD8 T cells that are associated with 
functional capacity in the context of latent infection and active disease in order to 
better understand the role of CD8 T cells in control of MTB infection.  
A multiparameter flow cytometry panel was designed and optimized to assess 
cell turnover, susceptibility to apoptosis and terminal differentiation/senescence in 
CD8 T cells from TB and LTBI donors. Bcl-2, Ki67, CD95, CD57, CD127 and IFNγ 
were measured in each group, and the antigen-specific CD8 T cells were compared 
to the total CD8 T cell population. We hypothesized that activated MTB-specific CD8 
T cells in TB would display an effector phenotype with a high rate of turnover, and be 
more prone to apoptosis, compared with LTBI.  
The results indicate that Bcl-2 and CD57 expression are increased in the total 
CD8 T cell population in individuals with TB disease, compared with LTBI, which 
may be due to inflammatory-mediated alterations of the tissue microenvironment. 
CD127 expression was increased on MTB-specific CD8 T cells, compared with the 
total CD8 T cell population, in individuals with LTBI, but not TB. Preliminary results 
shown in this chapter suggest that initiation of anti-TB treatment may reverse the 
phenotype seen in TB disease, implying that MTB-specific CD8 T cell phenotype is 
associated with mycobacterial antigen load. 
Together these data suggest that MTB-specific CD8 T cells from individuals with 
TB have a short-lived effector phenotype relative to MTB-specific CD8 T cells from 
individuals with LTBI. This may explain in part the reduced proliferative capacity in 
TB disease, as shown in the previous chapter. Additionally, active TB disease state 
influences the total CD8 T cell population by increasing the expression of Bcl-2 and 
CD57. The mechanisms by which mycobacterial antigen load and disease status 















Antigen stimulation in acute infection causes T cells to expand rapidly and then 
contract upon pathogen clearance, due to the withdrawal of cytokines required for 
proliferation and maintenance (Snow, Pandiyan et al. 2010). However in some 
instances the pathogen is not cleared, resulting in a chronic infection. During chronic 
infection, immune exhaustion characterized by a hierarchical loss of function has 
been described in antigen-specific T cells as a result of sustained T cell receptor 
(TCR) signaling by high antigen levels (Akbar and Henson 2011). The capacity to 
produce IL-2 is initially lost, followed by impaired proliferative ability, loss of TNFα 
production, and reduced cytotoxic activity. Only in the later stages of exhaustion is 
IFNγ production compromised (Wherry, Blattman et al. 2003), and eventually 
populations of exhausted antigen-specific T cells may be deleted. The functions lost 
may vary depending on the disease model, and are associated with antigen load and 
disease progression. For instance, human immunodeficiency virus (HIV)-infected 
long-term non-progressors (LTNP) display relatively limited T cell exhaustion 
compared with chronically infected adults with very high viral loads. The stage of 
infection (early vs. late) may also influence the level of exhaustion (Wherry, Blattman 
et al. 2003). 
 T cell exhaustion was first described in a mouse model of LCMV infection, in 
which virus-specific CD8 T cells did not have antiviral effector functions even though 
they expressed activation markers (Zajac, Blattman et al. 1998). Exhaustion has 
been studied in viral models of chronic infection such as LCMV, HIV, HCV and 
cytomegalovirus (CMV), in both animal and human models of infection (Fletcher, 
Vukmanovic-Stejic et al. 2005; Day, Kaufmann et al. 2006; Urbani, Amadei et al. 
2006). T cell dysfunction due to exhaustion is associated with  increased expression 
of inhibitory receptors such as PD-1 and CTLA-4 (Day, Kaufmann et al. 2006; 
Blackburn, Shin et al. 2009). Upon interaction with its ligands PD-L1 and PD-L2, PD-
1 signaling inhibits activation, proliferation and effector functions of antigen-specific T 
cells. (Barber, Wherry et al. 2006) CTLA-4 is an inhibitory marker that is upregulated 
in CD4 but not CD8 T cells in HIV infection (Kaufmann, Kavanagh et al. 2007); it is 
co-expressed with PD-1 in most cells, and its blockade results in increased HIV-












To date there has been little investigation of immune exhaustion markers in 
the context of MTB infection in humans. It has however been reported that PD-1 may 
play a role in regulating CD8 T cells in MTB infection. Blockade of the PD-1 signaling 
pathway resulted in an increased frequency of MTB-specific IFNү-producing T cells, 
and enhanced degranulation of CD8 T cells from individuals with TB (Jurado, 
Alvarez et al. 2008). The expression of inhibitory markers does not always indicate 
functional exhaustion, as certain markers are also correlates of late stage 
differentiated, functional T cells (Akbar and Henson 2011). Although prolonged 
expression of inhibitory receptors is a key aspect of exhausted T cells, activated cells 
can transiently express these receptors as well (Agata, Kawasaki et al. 1996). 
Terminally differentiated T cells have minimal proliferative capacity and are 
susceptible to apoptosis, however they may persist in vivo in the presence of 
appropriate survival signals (Akbar and Henson 2011). It has been suggested that 
this persistence allows sustained low level immune responses that will keep 
pathogen levels at a minimum (Snow, Pandiyan et al. 2010). CD57 is one of several 
markers of terminally differentiated CD8 T cells. CD57, also known as Leu-7, is 
found on natural killer (NK) cells as well as some CD3+ cells (Wood, Twigg et al. 
2009). The function of CD57 on T cells is unknown, however a sequence within it, 
known as HNK-1, has been found in various other cells such as neural tissue in the 
eye, and in cell adhesion molecules (Wood, Twigg et al. 2009).  
Previous studies in HIV infection have indicated that CD57 expression is a 
more accurate predictor of terminal differentiation than CD27 downregulation (Wood, 
Twigg et al. 2009). It has been suggested that CD57+ T cell frequencies could be 
used as a correlate of immune competence and risk for opportunistic infection 
(Focosi, Bestagno et al. 2010). Clonally expanded senescent T cells express CD57, 
have defects in proliferation (Wood, Twigg et al. 2009), and express high levels of 
Fas ligand, which renders cells susceptible to Fas-mediated apoptosis (Wood, Knox 
et al. 2005). Although CD57+ T cells and NK cells are less able to proliferate (Focosi, 
Bestagno et al. 2010), they are still able to produce IFNγ upon encounter with their 
cognate antigen (Brenchley, Karandikar et al. 2003). For example, CD57+ T cells 
secreted high levels of IFNү after stimulation with HIV antigens (Appay, Almeida et 
al. 2007). The proportion of CD57+ T cells increases with age, and increased 












immunocompromised individuals (Wood, Twigg et al. 2009). Increased expression of 
CD57 on the total CD8 T cell population has also been reported in individuals with 
newly diagnosed pulmonary TB, compared with healthy controls (Fateminasab, 
Shahgasempour et al. 2006). 
Replicative senescence is a characteristic of terminally differentiated cells, 
and has been described as the loss of replicative capacity of antigen-specific T cells 
due to repeated antigen stimulation (Akbar and Henson 2011). Senescence occurs 
as a natural function of age and repeated cell division, hence it has been frequently 
studied in elderly populations (Fletcher, Vukmanovic-Stejic et al. 2005; Appay, 
Fastenackels et al. 2011). Apart from terminal differentiation, senescence may also 
be due to a cell remaining permanently in G0 (resting phase) of the cell cycle. Cells 
may remain in the resting phase of the cell cycle temporarily or permanently and 
characteristically do not express the nuclear protein Ki67, whereas cells in the active 
phases of the cell cycle will express Ki67. Therefore Ki67 expression indicates the 
proliferative ability of a cell, and the proportion of Ki67+ cells in a given population 
identifies the fraction of this population that is currently cycling (Scholzen and 
Gerdes 2000). Increased Ki67 expression has been reported on total CD8 T cell 
populations from TB patients compared with healthy controls (Villacian, Tan et al. 
2005). Surprisingly, an increase in Ki67 expression in these patients was seen in the 
absence of an increase in other cellular activation markers such as CD38 (Villacian, 
Tan et al. 2005). Ki67 expression is indicative of, but not solely responsible for 
proliferation, as other signals may also play a role in preventing or encouraging 
proliferation (Scholzen and Gerdes 2000). Senescence-related signalling has been 
suggested to lead to apoptotic susceptibility (Akbar and Henson 2011).  
An indicator of susceptibility to apoptosis is Fas, also known as CD95 or 
Apo1. CD95 is a member of the TNF receptor family, all of which possess the death 
domain. Both CD95 and Fas ligand (CD95L) are induced in the course of an 
adaptive immune response, as they are necessary for contraction of the effector T 
cell population after a pathogen has been cleared (Hao and Mak 2010). 
The importance of CD95 and CD95L in apoptosis was first identified in mice with 
mutations in genes encoding these molecules. These mutations resulted in a 












(Takahashi, Tanaka et al. 1994). In TST positive healthy individuals, MTB stimulation 
caused CD95 mRNA upregulation in both CD4 and CD8 T cells, and antibody 
blockade of the CD95-CD95L interaction decreased cytolytic function for both T cell 
populations by 25% (Canaday, Wilkinson et al. 2001). TCR re-stimulation can cause 
CD95-mediated apoptosis of antigen-specific T cells, thus sparing by-stander cells 
that bear CD95 (Snow, Pandiyan et al. 2010). Restimulation induced cell death 
(RICD) is particular to antigen-experienced cells that undergo repeated stimulation 
with their cognate antigen. Susceptibility to RICD in memory cells can be measured 
using an ex vivo stimulation assay in a chronic disease model and identifying 
changes in expression of pro- and anti-apoptotic markers relative to the non-specific 
population (Snow, Pandiyan et al. 2010). The prevention of CD95-mediated RICD of 
bystander cells involves the expression of molecules which counter-act the pro-
apoptotic signals (Krueger, Fas et al. 2003). Bcl-2 is a well-known anti-apoptotic 
molecule capable of counteracting the effects of CD95-mediated signaling (Hao and 
Mak 2010; Snow, Pandiyan et al. 2010). 
Bcl-2 has been studied in the context of chronic lymphocytic leukemia, which 
involves the pathological accumulation of T lymphocytes. Bcl-2 accumulation results 
in reduced apoptosis (Wiegers, Kaufmann et al. 2011). Certain pro-apoptotic 
proteins influence the mitochondrial outer membrane potential, causing 
permeabilization and release of toxic molecules into the cytosol, thus leading to 
apoptosis. Anti-apoptotic proteins prevent this permeabilization, thus preventing 
apoptosis. It has been suggested that the presence of Bcl-2 may increase the half-
life of memory CD8 T cells (Kurtulus, Tripathi et al. 2011). MTB infection of mice 
results in increased CD95 expression, and decreased Bcl-2 expression in total CD4 
T cells, relative to a control group of uninfected mice, suggesting greater 
susceptibility to apoptosis upon MTB infection (Das, Vohra et al. 1999). 
IL-7 signaling results in Bcl-2 upregulation within T cells that bear the IL-7 
receptor (Nanjappa, Kim et al. 2011). Expression of the alpha chain of the IL-7 
receptor (IL-7Rα, CD127) plays a non-redundant role in the maintenance of memory 
T cells via homeostatic proliferation (Nanjappa, Kim et al. 2011; Pellegrini, Calzascia 
et al. 2011). CD127 expression above a certain threshold has been associated with 
proliferation, whereas expression below this threshold results in cell survival, but not 












posses adequate levels of CD127, they will not proliferate, and the immunological 
memory represented by that memory pool will cease to exist (Wherry 2011). HIV-
infected LTNPs maintain highly functional proliferating CD8 T cells, in contrast with 
impaired proliferative capacity and low CD127 expression by HIV-specific CD8 T 
cells in individuals with high viral loads (Wherry, Day et al. 2006; Day, Kiepiela et al. 
2007). 
Effector CD8 T cells transiently downregulate homeostatic cytokine receptors 
such as CD127 (Shin and Wherry 2007). However, mouse models of acute viral 
infection indicate high CD127 expression of a small subset of effector T cells during 
acute infection identifies populations of effector cells that will differentiate into long-
lived memory cells (Kaech, Tan et al. 2003). CD127high cells were found to express 
higher levels of anti-apoptotic molecules including Bcl-2 (Kaech, Tan et al. 2003), 
and CD127 expression and Bcl-2 expression were found to correlate in LCMV-
specific CD8 T cells during memory cell development (Kaech, Tan et al. 2003). 
Additionally, administration of IL-7 to MTB-infected mice increased their survival 
(Maeurer, Trinder et al. 2000). 
In this chapter, we used an ex vivo flow cytometry-based intracellular cytokine 
staining and phenotyping assay to characterize the expression of a novel panel of 
markers in CD8 T cells from individuals with LTBI and TB. This panel incorporates 
several relevant markers, and hence allows us to develop an idea of the interplay 
between senescence, terminal differentiation, proliferation, apoptotic susceptibility 
and antigen specificity. The results from these studies provide important insight 
regarding the reduced functional capacity of MTB-specific CD8 T cells in individuals 



















4.2.1 Participant characteristics 
 
A total of 30 participants were recruited for these studies (Table 4.1). Ten adults with 
active pulmonary TB disease (TB) who had received less than one week of anti-TB 
treatment were recruited. Additional blood samples were obtained at two months and 
six months after initiation of treatment in five of these donors for use in a longitudinal 
analysis. Twenty healthy asymptomatic adults with latent MTB infection (LTBI) were 
recruited; LTBI participants were identified by a positive response to ESAT6 and/or 
CFP10 in an IFNү release assay (IGRA), and no previous history of TB diagnosis or 
treatment. 
 
Table 4.1. Participant characteristics. 
 
a p = 0.0014, compared with LTBI 
b Values denote mean (range)  
c p <0.0001, compared with LTBI 






















4.2.2 Intracellular cytokine staining and phenotyping assay 
 
In order to compare the phenotype of CD8 T cells between LTBI and TB donors, 
PBMCs were stimulated ex vivo for 6 hours with CFP10 or ESAT6 peptide pools to 
identify MTB-specific T cells; cells were stimulated with CMV pp65 peptide pool and 
SEB as non-MTB antigen-specific and positive control antigens, respectively. 
Stimulated cells were analyzed by flow cytometry and antigen-specific CD8 T cells 
were identified as CD8+IFNγ+ T cells. The expression of CD127, Bcl-2, CD95, CD57 
and Ki67 was assessed on the total CD8 T cell and antigen-specific CD8 T cell 
populations. Representative flow plots illustrating the gating strategy in one LTBI 
donor are shown in Figure 4.1.  
It is possible that differences in T cell viability can affect the expression of 
markers, as well as the number of cells acquired. In order for valid comparisons to 
be performed between the two groups, it is important that cell viabilities are similar. 
Figure 4.2 shows that there are similar frequencies and number of viable 
lymphocytes (CD3+VIVIDlow cells) acquired between the two groups.  
 
 
Figure 4.1. Flow cytometry gating strategy. Representative flow plots from individual with TB 
following stimulation with CFP10 peptide pool. (A) Singlets and lymphocytes were gated on based on 
forward scatter and side scatter characteristics, live (VIVIDlow) CD3+ cells were gated on, followed by 
CD8+ cells. (B) After this preliminary gating, IFNγ, CD57, CD127, Bcl-2, Ki67 and CD95 positive 




































Figure 4.2. T cell viability is similar in LTBI and TB PBMCs. Viability of cryopreserved PBMCs was 
assessed in LTBI (n=20) and TB (n=10) CD3+ lymphocytes using flow cytometry. Left: frequency of 
viable CD3+ T cells as a percentage of total lymphocytes. Right: number of viable CD3+ lymphocytes 
acquired for each donor. Statistical differences were assessed using the Mann Whitney test. 
Horizontal lines represent the median. 
 
4.2.3 Activated Ki67+ CD8 T cells in peripheral blood ex vivo do not differ by 
disease state 
 
In order to identify whether differences in the activation status of cells could explain 
the reduced proliferation seen in TB donors relative to LTBI, total CD8 T cell 
populations were analyzed for Ki67 expression. The proportion of ex vivo Ki67+ CD8 
T cells (actively dividing) was similar between groups (Figure 4.3), indicating that 
reduced proliferation in TB was not due to an increased proportion of actively 
dividing CD8 T cells, as measured by intracellular Ki67 expression, in peripheral 
blood in vivo. 
 
Figure 4.3. Ki67 expression in total CD8 T cells does not differ between disease states. The 
total CD8 T cell population in LTBI and TB donors was analyzed ex vivo using flow cytometry. The 
proportion of Ki67+ CD8 T cells is shown. Statistical differences were assessed by the Mann Whitney 









































































4.2.4 Increased CD57 and Bcl-2 expression by CD8 T cells in TB donors, compared 
with LTBI 
 
Differences in the microenvironment due to inflammation during active disease may 
cause phenotypic changes in the total CD8 T cell population. In order to identify 
whether MTB infection and disease state influenced the phenotype of the total CD8 
T cell population, expression of CD95, CD57, Bcl-2 and CD127 was compared 
between TB and LTBI donors using flow cytometry. In the total CD8 T cell 
population, susceptibility to Fas-mediated cell death, as measured by CD95 
expression, was not different between TB and LTBI donors. However, CD57 
expression was significantly higher in TB donors, compared with LTBI (Figure 4.4).  
 
 
Figure 4.4. CD8 T cells in individuals with TB express higher levels of CD57, but not of CD95, 
compared with LTBI. The expression of CD95 and CD57 on total CD8 T cell populations was 
analyzed by flow cytometry. The percentage of CD95+ CD8 T cells is shown on the left graph and the 
percentage of CD57+ CD8 T cells is shown on the right graph. Horizontal lines represent the 
medians. Statistical differences were assessed by the Mann Whitney test.  
 
CD57 expression has been shown to be a function of age, with low expression on 
lymphocytes in infants, whereas adults constitutively express CD57 in 15%-20% of 
lymphocytes (Focosi, Bestagno et al. 2010). The median age of the TB donors in this 
study was higher than LTBI donors (Table 4.1). To determine whether CD57 
expression by CD8 T cells is associated with age in this study, we correlated the 
frequency of CD8+CD57+ T cells in LTBI and TB donors with age and found a 
significant but weak positive correlation (Figure 4.5), suggesting the higher levels of 



















































their increased age relative to the LTBI donors. Unfortunately we did not have 
access to samples from younger TB patients, therefore we could not compare age-
matched donors. In the future we could specifically recruit older LTBIs that are age-
matched to the TB group to try to eliminate this possible confounder in CD57 
between the two groups.  
 
 
Figure 4.5 Association between CD57 expression on CD8 T cells and age. The frequency of 
CD57+ cells in the total CD8 T cell population was correlated with age in years for both LTBI (blue 
circles; n=20) and TB donors (red circles; n=10). A linear regression analysis was performed. 
 
CD127 expression on CD8 T cells was similar between the groups, despite 
increased Bcl-2 expression in individuals with TB (Figure 4.6). This indicates the 
involvement of a CD127-independent pathway of Bcl-2 upregulation. However, a 
linear regression analysis indicated CD127 expression was moderately related to 
Bcl-2 expression, independent of disease status (Figure 4.7). These data suggest 
that although a greater proportion of the total CD8 T cell population in TB donors is 
terminally differentiated, these cells may be protected from Fas-mediated 
programmed cell death, as evidenced by lack of CD95 upregulation and increased 
Bcl-2 expression, compared with LTBI donors.  
 




















r2  =  0.2592  













Figure 4.6.  CD8 T cells in individuals with TB express higher levels of Bcl-2, but not of CD127, 
compared with LTBI. The expression of CD127 and intracellular Bcl-2 in total CD8 T cell populations 
was analyzed by flow cytometry. The percentage of CD127+ CD8 T cells is shown in the left graph 
and Bcl-2+ CD8 T cells in the right graph. Horizontal lines represent the medians. Differences were 
assessed with the Mann Whitney test. 
 
 
Figure 4.7. CD127 expression influences Bcl-2 expression. A linear regression was performed on 
CD127 and Bcl-2 expression on total CD8 T cell populations from both LTBI (blue circles; n=20) and 






























































r2  =  0.46  












4.2.5 Increased expression of CD127 on MTB-specific CD8 T cells in latent 
infection 
 
We next investigated phenotypic differences in MTB-specific CD8 T cells between 
individuals with TB and LTBI. PBMCs were stimulated for 7 hours with ESAT6 or 
CFP10 or CMV phosphoprotein-65 (pp65) peptide pools, after which IFNγ production 
was detected using flow cytometry, and used to identify antigen-specific CD8 T cells. 
5/10 TB donors and 7/20 LTBI donors had a positive response in this assay to either 
ESAT6 or CFP10. 10/10 TB donors and 18/20 LTBI donors had a CMV-specific CD8 
T cell response, and all donors had a response to the positive control Staphylococcal 
enterotoxin B (SEB).  
Compared to the total CD8 T cell population, CD127 expression was 
increased on MTB-specific CD8 T cells in LTBI donors, indicating an increased 
capacity for homeostatic proliferation (Figure 4.8A, B). In contrast, there was no 
difference in CD127 expression between MTB-specific and total CD8 T cells in 
individuals with TB (Figure 4.8A, B). However when compared to each other, CD127 
expression was similar in MTB-specific CD8 T cells between TB and LTBI donors 
(Figure 4.8C). In order to identify whether increased or maintained CD127 
expression was particular to MTB-specific CD8 T cells in LTBI or TB respectively, 
CD127 expression was compared in this subset to CMV-specific CD8 T cells, and 
SEB-stimulated cells within the same cohort (Figure 4.8D). In LTBI donors, MTB-
specific CD8 T cells display d greater CD127 expression levels relative to the CMV 
and SEB controls. This difference was not seen in TB disease (Figure 4.8D). 
Together these data indicate CD127 expression on antigen-specific CD8 T cells may 














Figure 4.8. Increased CD127 expression on MTB-specific CD8 T cells is associated with latent 
infection. After 7-hour stimulation with ESAT6 or CFP10 peptide pools, CMV pp65 peptide pool, or 
SEB, CD127 expression was determined on CD8+IFNγ+ cells and total CD8 T cells. (A) 
Representative histograms from one LTBI and one TB donor indicating CD127 expression of MTB-
specific CD8+IFNγ+ cells (black line) and the total CD8 T cell population (grey line). (B) After 
stimulation with ESAT6 or CFP10, CD127 expression on CD8+IFNγ+ cells was compared to the total 
CD8 T cell population in LTBI and TB. (C) The frequency of CD8+IFNγ+ CD127+ cells was compared 
between groups using a Mann Whitney test. Horizontal lines represent the medians. (D) Comparison 
of CD127 expression by CD8+IFNγ+ T cells between the various antigens for LTBI donors (left panel) 
and TB donors (right panel). Statistical differences in B and D were determined by the Wilcoxon 



























































































4.2.6 Ki67 expression is similar between antigen-specific CD8 T cells in individuals 
with LTBI and TB 
 
We next compared turnover of MTB-specific CD8 T cells in TB and LTBI donors by 
analysis of Ki67 expression (Figure 4.9A, B). If a greater proportion of MTB-specific 
CD8 T cells were activated in the context of active TB disease, then Ki67 expression 
should be increased in the MTB-specific cells from TB donors relative to LTBI 
donors. Contrary to this hypothesis, Ki67 expression levels did not differ between 
groups (Figure 4.9C). Additionally, there were no differences in Ki67 expression 
when comparing the total CD8 T cell population to MTB-specific CD8 T cells or 
between antigen stimulation conditions in either group (Figure 4.9B, D), implying that 
the percentage of actively dividing MTB-specific CD8 T cells circulating in peripheral 
blood may not be directly correlated with the other phenotypic and functional 















Figure 4.9. Ki67 expression in antigen-specific CD8 T cells is similar to total CD8 T cells and 
does not differ between latent and active TB. Intracellular Ki67 expression was measured in 
antigen-specific CD8 T cells following a 7-hour stimulation with ESAT6 or CFP10 peptide pools, CMV 
pp65 peptide pool or SEB, and in the total CD8 T cell population. (A) Representative histograms of 
Ki67 expression in MTB-specific CD8+IFNγ+ T cells (black line) and total CD8 T cells (grey line) from 
one LTBI and one TB donor. (B) After stimulation with ESAT6 or CFP10 peptide pools, the 
percentage of Ki67+ cells in MTB-specific CD8+IFNγ+ cells was compared to the percentage of Ki67+ 
cells in the total CD8 T cell population in LTBI and TB donors. (C) The frequency of CD8+IFNγ+ 
Ki67+ cells for each antigen specificity was compared between LTBI and TB donors; statistical 
differences were assessed using a Mann Whitney test. (D) Comparison of Ki67 expression by 
CD8+IFNγ+ T cells between the various antigens for LTBI donors (left panel) and TB donors (right 
panel). Statistical differences in B and D were determined by the Wilcoxon matched pairs test. 

































































































4.2.7 Expression of CD95 and Bcl-2 in MTB-specific CD8 T cells indicates 
increased susceptibility to RICD in TB compared with LTBI 
 
To test whether the antigen-specific CD8 T cells in individuals with active TB disease 
are more susceptible to apoptosis, CD95 and Bcl-2 expression levels were analyzed 
by flow cytometry. Compared to the total CD8 T cell population, Bcl-2 expression 
was similar in MTB-specific cells in both LTBI and TB (Figure 4.10A, B), whereas 
CD95 expression was increased on MTB-specific CD8 T cells compared with total 
CD8 T cells (Figure 4.11A, B). When MTB-specific CD8 T cells were compared 
between LTBI and TB donors, no significant differences were found in the 
expression of these two markers (Figure 4.10C, 4.11C). However, when using paired 
analyses to compare MTB-specific CD8 T cells to CD8 T cells of other antigen 
specificities within each cohort, interesting patterns of expression were found. MTB-
specific T cells in LTBI donors trended to display increased Bcl-2 expression relative 
to CMV and SEB stimulated cells and total CD8 T cells in the same individuals, 
whereas-MTB specific CD8 T cells in TB donors trended to display decreased Bcl-2 
expression relative to other antigen stimulated CD8 T cells and total CD8 T cells 
(Figure 4.10D). Together these data suggest MTB-specific CD8 T cells may be more 
susceptible to apoptosis compared with CD8 T cells of other antigen specificities 
within the same individual. 
Although CD95 expression was increased in MTB-specific CD8 T cells from 
both LTBI and TB cohorts, compared with the total CD8 T cell populations (Figure 
4.11B), the increase in CD95 expression could be attributed to short-term activation 
in vitro, and we thus compared CD95 expression on MTB-specific CD8 T cells to 
CD95 expression on CD8+IFNγ+ following SEB stimulation within the same 
individuals (Figure 4.11D). The increase in CD95 expression on MTB-specific CD8 T 
cells relative to total CD8 T cells in TB donors could not necessarily be attributed to 
activation, as MTB-specific CD8 T cells from these donors trended towards higher 
CD95 expression than SEB-stimulated cells, suggesting that this increase is related 
to re-activation following chronic/long term antigen stimulation, and not solely due to 














Figure 4.10. Differential patterns of Bcl-2 expression in MTB-specific CD8 T cells between 
individuals with LTBI and TB. Intracellular Bcl-2 expression was measured in total CD8 T cells and 
antigen-specific CD8+IFNγ+ T cells by flow cytometry following a 7-hour stimulation with ESAT6 or 
CFP10 peptide pools, CMV pp65 peptide pool or SEB. (A) Representative histograms of Bcl-2 
expression in total CD8 T cells (grey line) and MTB-specific CD8+IFNγ+ T cells (black line) from one 
LTBI and one TB donor. (B) After stimulation with ESAT6 or CFP10, Bcl-2 MFI on CD8+IFNγ+ cells 
was compared to the total CD8 population in LTBI and TB donors. (C) The frequency of CD8+IFNγ+ 
Bcl-2+ cells was compared between LTBI and TB donors using a Mann Whitney test. (D) Comparison 
of intracellular Bcl-2 expression in CD8+IFNγ+ T cells between the various antigens for LTBI donors 
(left panel) and TB donors (right panel). Statistical differences in B and D were determined by the 


































































Figure 4.11. CD95 expression is increased on MTB-specific CD8 T cells relative to total CD8 T 
cells in LTBI and TB donors. CD95 expression was measured on total CD8 T cells and antigen-
specific CD8+IFNγ+ T cells following a 7-hour stimulation with ESAT6 or CFP10 peptide pools, CMV 
pp65 peptide pool or SEB. (A) Representative histograms of CD95 expression on total CD8 T cells 
(grey line) and MTB-specific CD8+IFNγ+ T cells (black line) from one LTBI and one TB donor. (B) 
After stimulation with ESAT6 or CFP10, CD95 expression on CD8+IFNγ+ T cells was compared to 
the total CD8 T cell population in LTBI and TB donors. (C) The frequency of CD8+IFNγ+ CD95+ cells 
was compared between TB and LTBI donors using a Mann Whitney test. (D) Comparison of CD95 
expression by CD8+IFNγ+ T cells between the various antigens for LTBI donors (left panel) and TB 
donors (right panel). Statistical differences in B and D were determined by the Wilcoxon matched 
































































4.2.8 CD57 expression does not differ between antigen-specific CD8 T cells and 
total CD8 T cells in LTBI and TB donors 
 
When comparing total CD8 T cell populations between LTBI and TB donors, it was 
found that CD57 was expressed by a significantly higher frequency of CD8 T cells 
from TB donors than LTBI donors (Figure 4.4). We next compared CD57 expression 
on MTB-specific CD8 T cells from LTBI and TB donors. For both LTBI and TB 
donors, there were no differences in CD57 expression when comparing MTB-specific 
CD8 T cells to the total CD8 T cell population (Figure 4.12A, B). There was no 
differential expression of CD57 between MTB-specific CD8 T cells from LTBI and TB 
donors, however CMV and SEB stimulated CD8 T cells expressed higher levels of 
CD57 in TB than in LTBI donors (Figure 4.12C). This may be a reflection of the 
increased global CD57 expression as seen in the total CD8 T cell population of TB 
donors. There were no significant differences when comparing MTB-specific CD8 T 
cells to CMV and SEB stimulated cells within the same individuals (Figure 4.12D). 
Together these results suggest that TB disease is associated with a global increase 














Figure 4.12. CD57 expression in CD8 T cells does not differ by antigen specificity in LTBI and 
TB donors. CD57 expression was measured on total CD8 T cells and antigen-specific CD8+IFNγ+ T 
cells following a 7-hour stimulation with ESAT6 or CFP10 peptide pools, CMV pp65 peptide pool or 
SEB. (A) Representative histograms of CD57 expression on total CD8 T cells (grey line) and MTB-
specific CD8+IFNγ+ T cells (black line) from one LTBI and one TB donor. (B) The frequency of 
CD57+ cells in antigen-specific CD8+IFNγ+ cells was compared to the total CD8 T cell population in 
LTBI and TB donors. (C) The frequency of CD8+IFNγ+ CD57+ cells was compared between LTBI and 
TB donors using a Mann Whitney test. (D) Comparison of the percentage of CD8+IFNγ+ CD57+ cells 
between the various antigens for LTBI donors (left panel) and TB donors (right panel). Statistical 
differences in B and D were assessed by the Wilcoxon matched-pairs test. Horizontal lines represent 







































































































4.2.9 Initiation of anti-TB treatment influences the expression of markers of 
apoptosis and senescence 
 
To begin to address whether reduction in bacterial load following initiation of anti-TB 
treatment could alter the MTB-specific CD8 T cell phenotype seen in individuals with 
TB disease, expression of CD127, Ki67, Bcl-2, CD95 and CD57 was measured 
longitudinally at <1 week, 2 months, and 6 months after initiation of treatment in 5 
individuals. One of the donors did not have a detectable MTB-specific CD8 T cell 
response at any of the time points; another donor only had a detectable MTB-
specific CD8 T cell response at the 2 month and 6 month time points. In the 
remaining donors, it was found that susceptibility to apoptosis of MTB-specific CD8 T 
cells seems to decrease with treatment, as evidenced by increased CD127 and Bcl-2 
expression and decreased Ki67 and CD95 expression over time; however, due to 
the sample size, these trends did not reach statistical significance in MTB-specific or 
total CD8 T cell populations (Figure 4.13A, B). Overall, these preliminary findings 
suggest the effector phenotype of MTB-specific CD8 T cells is associated with 
mycobacterial antigen load, and successful response to anti-TB treatment may 
promote differentiation of MTB-specific CD8 T cells with greater long-term memory 













Figure 4.13. Apoptotic susceptibility of MTB-specific CD8 T cells may decrease with time on 
TB treatment. A longitudinal analysis was performed on CD8 T cells from blood taken at <1 week, 2 
months, and 6 months following initiation of anti-TB treatment. Expression of CD127, Ki67, Bcl-2, 
CD95, and CD57 was analyzed by flow cytometry on MTB-specific CD8 T cells (A; n=4) and total CD8 
T cells (B; n=5). No significant differences were found between total CD8 T cell populations over time 








































































Chronic viral infections have been shown to result in reduced CD8 T cell function 
(Shin and Wherry 2007). The trends shown in this exploratory research suggest that 
TB disease state is associated with increased apoptotic susceptibility and 
senescence of MTB-specific CD8 T cells; moreover, a longitudinal analysis of 
individuals with TB disease suggests that the long-term memory capacity of MTB-
specific CD8 T cells may at least be partially restored following reduction in 
mycobacterial load by successful anti-TB treatment.  
Apoptotic susceptibility was defined by an increased sensitivity to Fas-
mediated apoptosis through increased expression of CD95, and reduced levels of 
the anti-apoptotic molecule Bcl-2. Bcl-2 expression was increased in the total CD8 T 
cell population of TB donors compared to LTBI donors. It is hypothesized that this 
may be a protective reaction against the pyroptotic environment associated with the 
inflammatory milieu of active TB disease, which may prevent death in bystander 
lymphocytes.  
In TB donors, we found that MTB-specific CD8 T cells displayed increased 
CD95 expression compared with total CD8 T cells, which could not solely be 
explained by in vitro activation, and reduced Bcl-2 expression compared to CMV and 
SEB stimulated CD8 T cells. This corresponds with findings by Klinger et al, who 
measured apoptosis in peripheral blood monocytes of TB diseased patients following 
infection with BCG or stimulation with heat-killed MTB. They showed that apoptosis 
was associated with reduced Bcl-2 mRNA and protein expression, in the absence of 
a corresponding decrease in the expression of pro-apoptotic molecules that would 
counter-act Bcl-2 signaling (Klingler, Tchou-Wong et al. 1997). In healthy LTBI 
donors, we showed that MTB-specific CD8 T cells displayed increased Bcl-2 
expression relative to CD8 T cells of other antigen specificities within the same 
individuals, thus suggesting reduced apoptotic susceptibility of MTB-specific CD8 T 
cells in the context of latent infection. Together these data suggest that MTB-specific 
CD8 T cells in LTBI donors may have Bcl-2-mediated protection against apoptosis. 
Based on the down-regulation of Bcl-2 and the high CD95 expression levels in 
MTB-specific CD8 T cells from TB donors, it was expected that CD127 expression 












CD127 expression on MTB-specific CD8 T cells was similar to that of the total CD8 T 
cell population in TB donors, and increased relative to the total CD8 T cell population 
in the LTBI donors. This maintenance/increase of CD127 expression was unique to 
MTB-specific cells, as CMV-specific CD8 T cells and SEB-stimulated CD8 T cells 
from both groups tended to display reduced CD127 expression compared with the 
total CD8 T cell population. It was hypothesized that increased CD127 expression in 
MTB-specific CD8 T cells from LTBI donors represents a positive regulatory 
mechanism that prevents RICD, thereby promoting maintenance and survival of this 
pool of memory CD8 T cells in the context of low mycobacterial antigen loads in LTBI 
donors. If this is true, it would follow that the lack of increased expression of CD127 
in MTB-specific CD8 T cells from TB donors may render these cells more 
susceptible to apoptotic cell death.  
Because Bcl-2, IL-7 and Fas pathways are interrelated in terms of cell survival 
and homeostasis, the differential expression of one molecule may lead to differential 
expression of the other two molecules. The experiments in this study are 
observational in nature, and thus cause and effect relationships cannot be currently 
established; however this preliminary research will allow for comparisons to be made 
between human subjects and experimental animal models. 
Similar frequencies of Ki67+ CD8 T cells in TB and LTBI donors implies that 
these groups have a similar rate of cell turnover of CD8 T cells circulating in 
peripheral blood in vivo. Therefore the limited proliferation seen in TB disease 
donors in 6-day in vitro proliferation assays must be caused either by the absence of 
further pro-proliferation signals, or increased apoptosis. Although the results were 
not statistically significant due to our small sample size, Ki67 expression in MTB-
specific CD8 T cells decreased with time on treatment in TB diseased individuals, 
and the median Ki67 frequency was higher in MTB-specific CD8 T cells in TB 
disease compared to LTBI, which is consistent with previous findings showing that 
Ki67 is expressed in higher amounts in active TB compared to latent infection 
(Villacian, Tan et al. 2005). It is important to note that this study was performed on 
peripheral blood, which precludes analysis of cells that have migrated to the lungs 
during active disease. Therefore increased frequencies of Ki67+ MTB-specific CD8 T 
cells may have been present but undetectable, due to sequestration in the lungs at 












With regard to senescence, CD57 expression has been shown to be related 
to the natural waning of the immune system with age (Kudlacek, Willvonseder et al. 
2000), and it has been suggested that increased CD57 expression levels can be 
used as a correlate of susceptibility to infection (Focosi, Bestagno et al. 2010). Our 
findings corroborate with this, as TB donors had an increased frequency of CD57+ 
CD8 T cells compared with LTBI donors. It is well known that elderly people are 
more susceptible to infectious diseases, purportedly due to a waning of immune 
system function with time (Focosi, Bestagno et al. 2010). The fact that CD57 
expression is not different in MTB-specific CD8 T cells compared to the total CD8 T 
cell population within each group is surprising, as we hypothesized that high antigen 
levels in TB disease may drive MTB-specific CD8 T cells to become more terminally 
differentiated, as reflected by an increase in CD57 expression.  
There are several caveats to consider when interpreting these data, including 
the small sample size, particularly in the TB donors, which will need to be increased 
in order to validate these preliminary findings. Additionally, the use of IFNү as a 
marker for antigen specificity will exclude antigen-specific CD8 T cells that do not 
produce IFNγ. Moreover, detection of intracellular IFNγ production requires short-
term antigen stimulation, which may affect the expression of phenotypic markers on 
stimulated CD8 T cells. However, in the absence of tetramers, IFNү production is an 
ideal marker for antigen specificity in chronically stimulated, potentially exhausted 
CD8 T cells because IFNγ production is one of the last functions to be lost in 
exhausted T cells. Extremely exhausted, pre-apoptotic CD8 T cells from individuals 
with high viral loads in chronic HIV infection have been shown to produce IFNү 
(Akbar and Henson 2011). In this research, the characterization of polyfunctional 
cytokines would be useful in order to identify how functional cells of specific 
phenotypes are. IL-2 production and IL-2 receptor expression would be of particular 
interest, as this cytokine is associated with lymphocyte proliferation. Unfortunately 
we did not have the capacity to measure multiple cytokines in our multi-color CD8 T 
cell phenotyping flow cytometry panels. The limitation of looking at CD8 T cell 
responses in the blood of individuals with pulmonary TB is that MTB-specific effector 
cells are expected to migrate to the site of infection, resulting in the detection of only 












The differences between CD8 responses in active versus latent TB reflect 
inherent differences between the nature of effector and memory responses. For 
example in active TB the cells produce IFNγ ex vivo and proliferate poorly, which is 
characteristic of a late-stage differentiated phenotype. In latent infection proliferation 
of CD8 T cells is robust, whereas ex vivo cytokine production is poor, which implies a 
memory phenotype. Post treatment responses suggest possible restoration of the 
memory pool in individuals with TB, and further indicate that the effector and memory 
phenotype of CD8 T cells is related to mycobacterial antigen load.  
 
Overall these data indicate that during active pulmonary TB disease, the 
effector memory pool of MTB-specific cells in TB donors have a phenotype indicative 
of the early-intermediate stage of exhaustion, where proliferative capacity is low and 
pro-apoptotic susceptibility is high, relative to the total CD8 T cell population. By 
contrast, LTBI donors display a phenotype indicative of increased cell survival. In 
LTBI donors, apoptotic susceptibility, as measured by CD127, CD95 and Bcl-2 
expression, does not seem to be increased in MTB-specific CD8 T cells compared to 
the total CD8 T cell population. These results suggest that maintenance of MTB-
specific CD8 T cells with long-term memory capacity may be associated with 
successful immune control of MTB infection. Further studies are warranted to 
determine whether changes in expression of these markers on MTB-specific CD8 T 
cells is associated with loss of immune control and subsequent progression to active 
TB disease. Additionally, further longitudinal studies on anti-TB treatment would 
shed light on the relationship between MTB-specific CD8 T cell phenotype and 




































































Immune correlates of protection from TB disease progression must be identified in 
order to give better direction to preventative and therapeutic research. By detailed 
analysis of CD8 T cells in individuals with LTBI and TB disease, this project provides 
information on the functional capacity, breadth, magnitude and phenotype of MTB-
specific CD8 T cells, as well as how these attributes differ in the context of latent and 
active TB disease. 
Overall we have shown that CD8 T cells in LTBI have a greater proliferative 
response to immunodominant MTB proteins, and they recognize a greater breadth of 
peptides, compared with individuals with TB. MTB-specific CD8 T cells from 
individuals with TB disease respond to individual CFP10 or ESAT6 peptides by IFNγ 
production ex vivo, but maintain poor proliferative capacity, and express markers 
indicative of effector cells that may be in the early stage exhaustion. Our preliminary 
longitudinal analysis of a small number of individuals with TB on anti-TB treatment 
suggests that the expression of these markers may be reversed with increasing time 
on treatment. We have established and optimized flow cytometric panels for the 
characterization of effector functions of antigen-specific CD8 T cell responses, and 
these panels may be of relevance to apply to other cohorts of adults with TB and/or 
HIV infection to further understand the role of CD8 T cells in chronic infections. 
The information provided by this study must be assessed while keeping in 
mind several factors, including the sequestration of effector T cells to the lung within 
active disease, small sample sizes, and the use of IFNγ as a marker for antigen 
specificity. 
It is established that during active pulmonary TB, MTB-specific T cells will be 
sequestered to the site of infection, which is the lung. Wilkinson et al have shown 
that MTB specific IFNγ-producing cells are present at up to 15-fold higher 
concentrations in the broncho-alveolar lavage (BAL) fluid of patients with pleural TB 
compared to peripheral blood using an ex vivo Elispot assay (Wilkinson, Wilkinson et 
al. 2005). In patients with sputum smear-negative, culture-positive pulmonary TB, no 
differences were found in the distribution of CD4 or CD8 T cells between peripheral 
blood and BAL fluid. However, ESAT6 and CFP10-specific T cells were more 
concentrated in BAL fluid, with a BAL fluid: peripheral blood ratio of 9.9 and 8.9, 












frequency of MTB-specific T cells circulating in peripheral blood. However re-
circulation of antigen-specific T cells, and the use of highly sensitive assays, allowed 
for the detection of adequate numbers of antigen-specific CD8 T cells in both groups 
of LTBI and TB donors. Additional studies of cells isolated from the lungs by BAL 
should be performed in our donors to further characterize the phenotype and 
functional capacity of MTB-specific CD8 T cells that traffic to the site of infection and 
disease. 
With regards to sample size, it is known that increased numbers reduce the 
possibility of chance results. Current studies are ongoing with additional donors to 
verify these preliminary findings in larger cohorts. When establishing the cohorts, 
participants were not selected according to age or gender, and the donors were not 
HLA-typed. This randomization is the ideal method of sample gathering, as it is likely 
to produce demographics that are representative of each gr up of individuals. As a 
result, there were more males in our TB group, and this group was older than the 
group of LTBI donors.  
Because donors were sampled from the same community and represent 
similar ethnicities, we have assumed that the distribution of HLA types is similar 
between cohorts. Studies such as this one lay the groundwork for future studies that 
will characterize in detail the HLA restrictions of the most commonly targeted 
immunodominant CD8 T cell epitopes in MTB-infected individuals. Mapping and HLA 
restriction of CD8 T cells is necessary for the generation of tools such as MHC class 
I tetramers, which can be used to track individual CD8 T cell populations over time 
during TB disease treatment. Such tools can also be highly useful in evaluating TB 
vaccine immunogenicity or isolating epitope-specific populations for a detailed 
microarray analysis, thus allowing for a better characterization of the phenotype and 
function of these cells in latent and active disease.  
The use of IFNγ as a marker of antigen specificity implies that CD8 T cells 
with other functions, such as cytotoxicity, will not be detected. This can be remedied 
in future research by measuring the production of cytotoxic molecules such as 
perforin, granzymes, granulysin, as well as CD107 expression; in addition, 












how effective MTB-specific CD8 T cells may be in controlling bacterial replication in 
vivo.  
Not all extraneous variables can be accounted for in any given human 
immunology study. Therefore the results provided are observational in nature, and 
often cause and effect relationships are difficult to establish in this context. Because 
T cell phenotype and function is dynamic, there is an underlying uncertainty as to the 
validity of cross-sectional analysis of antigen-specific T cells at a single point in time. 
This is compounded by the fact that MTB infection is not static but rather represents 
a dynamic process, even in the absence of clinical symptoms (Barry, Boshoff et al. 
2009). Longitudinal studies are therefore important, for example to identify 
biomarkers or immunological factors indicative of successful treatment response in 
TB patients on anti-TB treatment, or to identify factors associated with recurrence or 
relapse of disease in these patients. Longitudinal studies of latently infected 
individuals prior to development of TB disease are important to identify 
immunological factors or biomarkers that precede development of disease, and may 
be useful indicators of risk of disease progression. 
Lastly, there are several follow up questions that this project has generated: 
(1) in Chapter three a large breadth of subdominant peptide responses were 
observed in a sensitive proliferation assay, whereas an ex vivo Elispot assay showed 
distinctly immunodominant peptides in each donor, and minimal responses to non-
immunodominant peptides. It would be interesting to study the role of CD8 T cells 
targeting subdominant epitopes, and whether they are a correlate of protection, as 
has been suggested in other models of chronic infections such as HIV (Frahm, 
Kiepiela et al. 2006; Im, Hong et al. 2011). (2) CD127 expression was higher in MTB-
specific CD8 T cells compared to the total CD8 population, the CMV specific 
population and the SEB-stimulated population in LTBI, but not in TB. Latently 
infected individuals have lower antigen levels, and in theory memory capacity may 
be preserved, compared with individuals with TB. Additionally, Bcl-2 expression in 
MTB-CD8 T cells from LTBI donors was increased relative to other CD8 T cell 
populations within this cohort; the opposite trend in Bcl-2 expression was seen in 
MTB-specific CD8 T cells from TB donors. Future studies may involve testing 
whether these differences are due to a skewing of the response to an effector 












infection. (3) In the context of these results, further studies are warranted to 
specifically evaluate markers of exhaustion, such as PD-1, CTLA-4 and LAG-3, in 
these cohorts in order to address whether chronic MTB infection and high antigen 
loads in TB disease can drive CD8 T cells to a state of functional exhaustion.  
In conclusion, these results represent a detailed characterization of MTB-
specific CD8 T cells with regard to antigen specificity, functional capacity and 
phenotype in the context of latent and active TB disease in humans. This project has 
positively influenced the community in which it was performed, and generated results 
which allow for the development of a platform for future studies to delineate 
associations between MTB-specific CD8 T cell function and disease progression 
using prospective, longitudinal cohorts sampled prior to and following development 
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